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2. ABSTRACT 
 
Mutations in the TP53 gene are among the most frequent genetic alterations in human 
cancers. As a consequence of these mutations p53 loses its tumour suppressor 
functions and may acquire novel oncogenic activities (gain of function) sustaining 
tumour formation and progression. Many in vivo studies highlighted that mutant p53 
gain of function is associated with elevated protein levels, supporting the notion that 
in tumour cells altered signalling could stabilize and activate mutant p53, with 
mechanisms similar to those required to stimulate wild-type p53. 
The aim of my PhD work was to investigate the mechanisms underlying mutant p53 
gain of function, focusing on factors that might link cancer-related signalling with 
mutant p53 activity. An intriguing candidate for this role is the phosphorylation-
dependent prolyl isomerase Pin1, that transduces phosphorylation signalling into 
conformational changes affecting the functions of its substrates, as ours and other 
laboratories have reported for wild-type p53. Despite Pin1 supports wild-type p53 
functions, Pin1 is frequently overexpressed in human tumours and has been shown to 
promote both Her2/Neu/Ras and Notch1 dependent transformation. So we reasoned 
that the physiological role of Pin1 as a component of checkpoint mechanisms might 
be subverted during tumourigenesis, thereby turning it into an essential partner of 
mutant p53 and a critical amplifier of its oncogenic functions. 
Indeed, we now demonstrate that Pin1 enhances tumourigenesis in a Li-Fraumeni 
mouse model and cooperates with mutant p53 in Ras-dependent cell transformation. 
In human breast cancer cells, Pin1 promotes both mutant p53 dependent inhibition of 
the anti-metastatic factor p63 and the induction of a mutant p53 transcriptional 
program to increase tumor aggressiveness. Accordingly, we have identified a 
transcriptional signature (the Pin1/mutant p53 signature) that is associated with poor 
prognosis in breast cancer and, in a cohort of patients, Pin1 over-expression 
influences the prognostic value of p53 mutation. 
Considering that TP53 mutation is more frequent in tumors with higher risk of 
recurrence such as triple-negative cases and that some of the Pin1/mutant p53 
signature genes are over-expressed in triple negative breast cancers, our findings carry 
therapeutic implications for this kind of cancers and possibly also for other tumours 
bearing mutant p53 and high levels of Pin1. 
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3. INTRODUCTION 
 
3.1. The tumour suppressor p53 
 
Despite intensive efforts devoted to cancer research in the last decades, according to 
the 2008 World Cancer Report of the IARC, in the next years cancer will become the 
first cause of death worldwide (www.iarc.fr). It is now clear that this disease is a 
highly complex genetic disorder, characterized by defects in regulatory circuits 
(cellular checkpoints), which finely modulate normal cell proliferation and 
homeostasis. As a consequence, virtually all human tumours share six common 
features: self-sufficiency in growth signals, insensitivity to growth inhibitors, evasion 
of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
Recently, it has been suggested that, in addition to these six hallmarks, tumour 
formation may benefit also from the inflammatory microenvironment (Mantovani, 
2009) and from change in cell metabolism to sustain deregulated cell proliferation 
(Hanahan and Weinberg, 2011). 
From a molecular point of view, tumourigenesis is a multistep process in which every 
step is associated to mutations affecting the function of proteins that can be 
envisioned as crucial hubs in the complex network of the cancer cell. In general, these 
mutations occur in proto-oncogenes or in tumour suppressor genes. In the first group 
there are genes like Ras, Myc, Src and erbB2, which once mutated display an 
enhanced and uncontrolled expression and/or activity, thus promoting growth and 
survival of cancer cells. Conversely, tumours need to inactivate tumour suppressor 
genes like p53, Rb or PTEN that physiologically would be activated in stress 
conditions to limit cellular proliferation and survival. 
One of the most important signalling pathways against tumour formation and 
progression is the p53 tumour suppressor pathway. Its pivotal node, namely the p53 
protein, was discovered in 1979 by three independent groups as an interacting partner 
of the viral SV40 T-antigen (Kress et al., 1979; Lane and Crawford, 1979; Linzer and 
Levine, 1979). For almost a decade, p53 was considered to be a tumour antigen with 
transforming capabilities. Only during the late 1980s it was revealed that p53 is 
indeed a tumour suppressor and that the evidence for its supposed oncogenic 
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functions had been erroneously collected from tumour-derived mutant clones (Weisz 
et al., 2007). 
After more than thirty years of research, extensive knowledge has been more and 
more achieved regarding the complexity of the p53 pathway (figure 1). 
 
Figure 1. Simplified scheme of the p53 pathway. The p53–MDM2 feedback loop is the “heart” of the 
p53 pathway. Under normal conditions, it maintains constantly low steady-state p53 levels and activity. 
Various stress signals, related in many ways to carcinogenesis, impinge on this central loop to release 
p53 from MDM2-mediated inhibition. This increases p53 protein levels and activity, inducing various 
phenotypic changes. The nature of the phenotypic response to p53 activation is, at least partially, 
proportionate to the amplitude, duration and nature of the activating signal. Recent evidence indicates 
that p53 has an important role also in enabling the cell to adjust its metabolism in response to mild 
normal physiological fluctuations, including those in glucose and other nutrient levels, oxygen 
availability and reactive oxygen species levels. (Levine and Oren, 2009) 
 
p53 can be envisioned at the centre of a highly interconnected network that conveys 
and transduces signals, which can represent stress conditions. Indeed, these signals 
can originate from external factors (such as γ-rays, UV light, DNA damaging agents, 
…) or internal ones (like oncogene activation, high levels of reactive oxygen species 
(ROS), ribonucleotide depletion, …) and may compromise genomic stability and 
promote neoplastic transformation. In response to these stresses p53 becomes 
stabilized and activated, events that are regulated by a refined combination of post-
translational modifications and interacting protein partners (Kruse and Gu, 2009). 
One of the most crucial steps is its evasion from the continuous ubiquitylation by its 
major E3 ubiquitin ligase Mdm2 and the subsequent degradation by the 26S 
proteasome (Haupt et al., 1997; Kubbutat et al., 1997). Once activated, p53 acts 
essentially as a transcription factor able to promote the coordinated expression of an 
array of target genes that are the executors of p53-induced cellular responses, such as 
cell cycle arrest, senescence or apoptosis (Levine and Oren, 2009). Although all these 
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activities are believed to rely mainly on the ability of p53 to function as a 
transcription factor, transcription-independent activities can also contribute to its 
apoptotic functions (Marchenko et al., 2007; Moll et al., 2005). Because of its role as 
a key integrator in translating diverse stress signals into different cellular outcomes, 
p53 has been called “cellular gatekeeper” (Levine, 1997) or “guardian of the genome” 
(Lane, 1992). 
Moreover, in the last years p53 was found involved also in the regulation of other 
cellular processes as metabolism, autophagy, fertility and stemness (Cicalese et al., 
2009; Crighton et al., 2006; Green and Kroemer, 2009; Hu et al., 2007; Vousden and 
Ryan, 2009). 
The relevance of the p53 pathway in tumour suppression is underscored by the 
observation that germline mutations in the p53 gene (TP53) are causative of the Li-
Fraumeni syndrome, whose patients are characterized by 25-fold increase in the 
chance of developing early onset cancers, compared with the general population 
(Malkin et al., 1990). Accordingly, p53 knockout mouse models have demonstrated 
that absence of p53 predisposes to spontaneous development of neoplastic disease 
(Donehower et al., 1992). Furthermore, somatic mutations in TP53 are one of the 
most common alterations in human cancer, occurring in more than 50% of cases 
(Soussi and Wiman, 2007). In the other half of tumours, the p53 pathway is 
functionally curbed because of either the amplification of negative regulators such as 
MDM2 (Muthusamy et al., 2006) or the inactivation of upstream factors like Chk2, 
ATM or p14ARF (Carr et al., 2006; Grochola et al., 2010; Vahteristo et al., 2001). 
Recent studies clearly demonstrated that restoration of p53 levels is able to interfere 
with tumour progression in vivo: the re-expression of p53 in tumours lacking p53 
expression triggered a fast and massive regression of established tumours caused by 
induction of p53-dependent apoptosis or senescence (Martins et al., 2006; Ventura et 
al., 2007; Xue et al., 2007). In tumours bearing mutant p53, re-introduction of a wild-
type protein is able to halt tumour growth (Wang et al., 2011). These observations 
suggest that p53 restoration would be effective in tumour therapy and boost the search 
for new strategies to activate the p53 pathway in vivo in tumours. In the last years, 
several approaches have been proposed to this purpose: increase of p53 stability and 
activity with peptides, natural compounds or molecules, like Nutlins and RITA 
(Brown et al., 2009; Grinkevich et al., 2009; Issaeva et al., 2004; Lain et al., 2008; 
Vassilev et al., 2004), or restoration of wild-type properties in p53 mutants achieved 
Introduction 
 11 
by means of small molecules like PRIMA-1, MIRA-1, STIMA-1 and CP-31398 or 
peptides (Bykov et al., 2002; Demma et al., 2010; Guida et al., 2008; Rippin et al., 
2002; Zache et al., 2008). 
 
 
The p53 family 
 
For a long time, p53 was believed to be a unique protein with no obvious paralogue. 
However, later it became clear that p53 belongs to a multigene family that includes 
other two members, namely p63 and p73 (Kaghad et al., 1997; Yang et al., 1998). 
Although all three proteins are able to bind to DNA in a sequence specific manner 
(recognizing similar consensus sequences) and have a similar modular organization, 
their primary structures do not share an elevated homology: it is about 30% for the 
whole sequence, but it reaches 65% when only the DNA binding domain is 
considered (IARC TP53 Database, www.p53.iarc.fr). 
Phylogenetic analyses revealed that p53-like genes are present also in lower 
organisms (as Dmp53 in D. melanogaster and Cep53 in C. elegans), however these 
orthologues would be more closely related to p63, suggesting that – among the three 
human proteins – the latter is the most similar to the ancestor gene of the family, 
while p53 is the most recent and has apparently evolved in vertebrates in order to 
efficiently respond to DNA damage (Yang et al., 2002). 
As a consequence of the partial structural homology, p53 family members have some 
overlapping functions mediated by the transactivation of common target genes 
(Stiewe, 2007). Indeed, p63 and p73 are able to trigger apoptosis upon DNA damage 
(Yang and McKeon, 2000) and to induce senescence both in vitro and in vivo (Fang et 
al., 1999; Guo et al., 2009). Recently, a critical role for p63 in metastasis suppression 
has emerged (Adorno et al., 2009; Muller et al., 2009). Consistently, the critical role 
of p63 and p73 in tumour suppression is highlighted by the findings that compound 
p63+/-p73+/- mice develop spontaneous tumours and that loss of p63 and p73 can also 
cooperate with loss of p53 in the development of specific tumour types (Flores et al., 
2005). 
In addition to their oncosuppressive activities and according to their earlier 
appearance during phylogenesis, p63 and p73 exert peculiar functions also in 
embryonic development and differentiation control. Although mice lacking p63 are 
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born alive, they show the most severe developmental phenotype of all p53 family 
members (Mills et al., 1999; Yang et al., 1999). The limbs are absent or truncated 
owing to a malfunction of the apical ectodermal ridge. Moreover, these mice fail to 
develop a stratified epidermis and most epithelial tissues (e.g. hair follicles, teeth, 
prostate and mammary glands) and eventually die from dehydration within hours after 
birth. All these abnormalities indicate the pivotal role for p63 in epidermal 
development, which has been associated either to the commitment of cells within the 
ectoderm to an epidermal lineage (Mills et al., 1999) or to the maintenance of 
epidermal stem cells (Yang et al., 1999). 
p73 knockout mice are viable, but show a runting phenotype and a high mortality rate 
within the first two months (Yang et al., 2000). These animals suffer from several 
neurological defects (hydrocephaly, hippocampal dysgenesis and loss of sympathetic 
neurons) and have immunological problems characterized by chronic infections and 
inflammation. Moreover, these mice show abnormal reproductive and social 
behaviour, which is presumably due to defects in pheromone detection in the 
vomeronasal organ. 
 
 
Functional domains of the p53 protein 
 
The human p53 gene span 20 Kbases on chromosome 17 (17p13.1) and consists of 11 
exons, which encode a protein of 393 residues (Vogelstein and Kinzler, 1994). As 
many other transcription factors, p53 has a modular structure composed by 
evolutionarily conserved functional domains: an N-terminal transactivation domain 
(aa 1-61), a proline-rich domain (aa 64-93), a central DNA-binding domain (aa 93-
292), an oligomerization domain (aa 325-355) and a C-terminal regulatory domain 
(figure 2). 
 
 
Figure 2. Domain organization of the p53 protein. Transactivation domain 1 and 2 (TAD1 and 
TAD2), proline-rich region (PRR), DNA-binding domain (DBD), oligomerization domain (OD) and a 
C-terminal domain (CTD). (Rajagopalan et al., 2010) 
 
The N-terminal transactivation domain of p53 contains two acidic domains (TAD1, 
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aa 1-40 (Unger et al., 1993), and TAD2, aa 40-61 (Candau et al., 1997)), both 
required to induce transcription of target genes. These two regions, indeed, interact 
with components of the transcriptional machinery, such as TBP (TATA box binding 
protein), TAFs (TBP-associated factors) (Chang et al., 1995), the p62 subunit of the 
transcriptional/repair factor TFIIH (Jawhari et al., 2004) and the transcriptional 
coactivators CBP (CREB binding protein) and p300 (Avantaggiati et al., 1997; 
Scolnick et al., 1997). This region contains also the binding site for the major negative 
regulator of p53, the ubiquitin ligase Mdm2, and the related transcriptional repressor 
Mdmx (Toledo and Wahl, 2006). 
The transactivation domain is followed by a proline-rich domain (PRD, aa 64-93), 
which contains five repeats of the amino acid motif PXXP (P= proline; X= any amino 
acid). The PRD is required for p53 stabilization, since the prolyl isomerase Pin1 binds 
to Thr81-Pro82 site upon Thr81 phosphorylation and induces a conformational 
change on Pro82, thus reducing Mdm2 binding (Berger et al., 2005; Zacchi et al., 
2002; Zheng et al., 2002). Furthermore, this region may affect p53 acetylation by 
p300 (Dornan et al., 2003) and is particularly involved in the ability of p53 to trigger 
apoptosis, both by transcriptional induction of pro-apoptotic genes (Bergamaschi et 
al., 2006; Venot et al., 1998) and by direct activity of p53 at mitochondria (Chipuk et 
al., 2004). 
Recently, a mouse strain was created expressing a p53 lacking the PRD (mouse 
p53ΔP): lack of PXXP motifs did not significantly affect p53 accumulation, 
transactivation, cell cycle control or apoptosis, thus questioning the in vivo role of this 
domain (Toledo et al., 2007). 
In the PRD is also present the best-characterized p53 polymorphism: in humans, 
codon 72 can encode either proline or arginine (Matlashewski et al., 1987). The 
distribution of this polymorphism appears to follow a north/south gradient, with the 
frequency of the Pro72 allele increasing toward the equator, suggesting a possible 
selection of codon Pro72 variants in areas with high UV light exposure (Beckman et 
al., 1994). This polymorphism affects p53 activity: Arg72 variant is more efficient 
than Pro72 in inducing apoptosis due to both its enhanced localization at 
mitochondria (Dumont et al., 2003) and its lower affinity for the iASPP protein, 
which binds preferentially to the PRD and selectively blocks access of p53 to the 
promoters of apoptosis-related genes (Bergamaschi et al., 2006). Consistently, 
expression of p53 Arg72 is associated to a greater sensitivity of tumour cells to 
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anticancer drugs and is predictive of a more favourable clinical response to 
chemotherapy in head and neck squamous cell carcinomas (Sullivan et al., 2004). 
Moreover, the p53 Arg72 allele is preferentially targeted for mutational inactivation 
and it has been shown that the ability of some p53 mutants to bind to p73 is restricted 
to the p53 Arg72 variant (Bergamaschi et al., 2003a). 
The central core of p53 contains its DNA binding domain (aa 93-292), required to 
recognize and specifically bind to the cognate sequence 5’ – PuPuPuC(A/T)-
(T/A)GPyPyPy – 3’ (el-Deiry et al., 1992). Besides the interaction with DNA, the 
DBD mediates the binding between p53 and crucial cofactors in defining p53 
functions and activity. Proteins like 53BP1, Hzf, ASPP1 and ASPP2 positively affect 
p53 activity by interacting with its DBD (Das et al., 2007; Samuels-Lev et al., 2001; 
Ward et al., 2005), while other proteins, like MDM2, bind to the DBD and negatively 
regulate p53. Indeed, Mdm2 has been surprisingly shown to interact also with 
residues in the DBD (Shimizu et al., 2002) and that the binding of Mdm2 to full-
length p53 is 10-fold stronger than binding to the N-terminal domain alone (Dawson 
et al., 2003). 
The frequency of tumour-acquired mutations of TP53 is the highest within this 
domain, highlighting the critical importance of loss of DNA binding and interaction 
with pivotal partners for enabling tumour cells to evade stress-induced growth 
suppression (Brosh and Rotter, 2009). 
The oligomerization domain (OD, aa 325-355) is required for the formation of a 
high-affinity DNA binding and transcriptional competent p53 tetramer. The 
importance of tetramerization for p53 tumour suppressor activities has been 
highlighted in studies showing that DNA damage-induced phosphorylation of Ser15, 
Ser20, and Ser33 requires the OD but not other domains (Shieh et al., 1999). 
The C-terminal domain of p53, in particular the last 30 amino acids (CT, aa 364-
393), has been historically called “regulatory domain”, since it contains several 
residues targeted by post-translational modifications that modulate p53 stability and 
function (Kruse and Gu, 2009). 
In the C terminus of p53 is present a cluster of three nuclear localization signals 
(NLS) that mediate the shuttling of the protein into the cell nucleus. NLSI (aa 316-
322) is the most active signal while the other two NLSs, II and III (aa 370-384) 
appear to be less important for nuclear localization (Shaulsky et al., 1990). p53 
contains also two putative nuclear export signals (NES), one in the N-terminus 
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(nNES, aa 11-27) and  the other in the OD (cNES, aa 340-351) (Stommel et al., 1999; 
Zhang and Xiong, 2001). For both NES, it has been proposed that when p53 needs to 
be activated, they are masked by the formation of the tetramer, or by direct 
phosphorylation by DNA-damage activate kinases. More generally, the 
oligomerization of p53 has been proposed as a mechanism that may regulate its 
nucleo-cytoplasmic transport by affecting the accessibility of the cNES but also of the 
NLS to their respective receptors (Stommel et al., 1999; Zhang and Xiong, 2001). 
 
 
p53 isoforms 
 
Few years ago, it has been revealed the existence of a complex pattern of different 
p53 isoforms due to use of several promoters and to alternative splicing (figure 3). 
 
Figure 3. (A) Scheme of the human p53 gene structure. Alternative splicing (α, β, γ) and alternative 
promoters (P1, P1’ and P2) are indicated. (B) Structural and functional domains of p53 protein 
isoforms. (Bourdon, 2007) 
 
The p53 protein can be codified from transcripts that can be initiated from two 
distinct sites upstream of exon 1 (P1 and P1’), but also from an internal promoter 
located in intron 4 (P2). The use of alternative promoters can lead to the expression of 
two different N-terminally truncated p53 proteins: Δ40p53 and Δ133p53. Δ40p53, 
which misses part of the transactivation domain (TAD1), can be obtained also by 
alternative initiation of translation or alternative splicing of the intron 2. The usage of 
P2 mediates the expression of Δ133p53, isoform that initiates at codon 133 and lacks 
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the entire transactivation domain (TAD1 and TAD2), the proline rich domain and part 
of the DNA-binding domain. Moreover, the alternative splicing of intron 9 can 
produce three isoforms different in their C-terminus: p53 (or p53α), p53β and p53γ, 
with p53β and p53γ isoforms lacking the oligomerization domain (Bourdon et al., 
2005; Ghosh et al., 2004). 
Interestingly, an additional p53 isoform (Δp53) has been described, which is 
characterized by a deletion of 66 aminoacids within the core domain (corresponding 
to aa 257-322) and showed a transcriptional activity different from that of full-length 
p53 (Rohaly et al., 2005). Indeed, it induces only p53 target genes involved in cell-
cycle arrest, thereby participating in a specific intra-S phase checkpoint. 
Until now, the spatial and temporal expression levels of the different p53 isoforms are 
largely unknown and their functional roles still await further characterization. 
 
 
Upstream events engaging the p53 pathway  
 
The activation of the p53 pathway is promoted by a wide range of stress signals 
affecting genome integrity and proper cell proliferation. The p53 protein functions as 
the pivotal hub of this intricate net, where incoming upstream stimuli are integrated 
and translated into the most appropriate responses (figure 4). 
 
Figure 4. The p53 activation and response. p53 mediates the response to various stress signals, many 
of which are encountered during tumour development and malignant progression. In general, these 
signals induce the stabilization of the p53 protein, and, as a consequence, the effect of p53 activation is 
to inhibit cell growth, either through cell-cycle arrest or induction of apoptosis, thereby preventing 
tumour development. (Vousden and Lu, 2002) 
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DNA damage and oncogenic signalling  
The term “DNA damage signalling” defines a great variety of events that might 
compromise genome integrity both by generating mutations and by causing double 
strand breaks (DSBs) in the DNA molecule, with consequent possible genomic 
rearrangements or loss of genetic information. The sources of DNA damage can be 
divided in two classes: exogenous and endogenous damage. The exogenous damage 
originates from external agents such as chemical mutagenic compounds, UV or 
ionizing radiations, while endogenous DNA damage derives from normal cellular 
processes linked to metabolism and replication. For instance, nucleotide oxidation can 
derive from reactive oxygen species (ROS), by-products of the normal oxidative 
metabolism. Replication stress due to premature termination of replication fork 
progression can also cause DNA damage, because it can result in fork collapse and 
DNA breakage (Branzei and Foiani, 2005). Moreover, cells activate DSB-induced 
responses also because of telomere erosion due to continuous replication (d'Adda di 
Fagagna et al., 2003; Takai et al., 2003). Remarkably, recent reports demonstrated 
how in human early precancerous lesions (but not normal tissues), the DNA damage 
response (DDR) signalling cascade is permanently activated, as a kind of barrier to 
counteract cancer progression, suggesting that cellular transformation is continuously 
generating DNA damage (Bartkova et al., 2005; Gorgoulis et al., 2005). Two 
important sources of constitutive DNA damage in cancer cells are the high production 
of ROS detected in cells transformed by various oncogenes, and the DNA replication 
stress, caused by aberrant firing of DNA replication origins, triggered by oncogene 
activation or loss of tumour suppressors (Bartkova et al., 2006; Di Micco et al., 2006; 
Mallette et al., 2007). 
Historically, DNA damage was the first type of stress found to activate the p53 
pathway (Lane, 1992). Signalling pathways activated by DNA damage (defined 
altogether as DNA Damage Response, DDR) communicate this potentially dangerous 
context converging on p53 through the induction of a complex combination of p53 
post-translational modifications. The two DNA damage sensor kinases, ATR and 
ATM, and their downstream kinases Chk1 and Chk2, are indeed able to 
phosphorylate p53 in different sites (Kruse and Gu, 2009): ATM and Chk2 activate 
p53 upon ionizing radiation and DSBs (Banin et al., 1998; Chehab et al., 2000; Hirao 
et al., 2000), while ATR and Chk1 are required in UV damage, hypoxia response, 
fork stalling and single strand DNA formation (Hammond et al., 2002; Pabla et al., 
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2008; Zou and Elledge, 2003). 
Other examples of kinases activating p53 during DDR are: DNAPK in the case of 
ionizing radiations (Okorokov et al., 2002), p38 upon UV radiation (Bulavin et al., 
1999; Huang et al., 1999), JNK because of oxidative stress (Buschmann et al., 2000b) 
or UV radiation (Buschmann et al., 2000a) and HIPK2 upon DNA damage (D'Orazi 
et al., 2002; Hofmann et al., 2002). 
Taken together these data suggest that both DNA damage and oncogenic signalling 
converge in p53 activation and are necessary for sustained p53 tumour suppressive 
activity. 
 
Other kinds of stimuli 
Other stimuli have been reported to induce activation of the p53 pathway. One of the 
best-characterized stimuli is nucleolar disruption (Zhang and Lu, 2009). The 
nucleolus works as a central stress sensor for a variety of agents, and nucleolar 
disruption also leads to p53 stabilization (Rubbi and Milner, 2003a): upon damage 
ribosomal proteins, such as L5, L11 and L23, are released from the nucleolus and 
bind to Mdm2, thus stabilizing p53 through the inhibition of the E3 ligase activity of 
Mdm2 (Bhat et al., 2004; Dai and Lu, 2004; Dai et al., 2004; Fumagalli et al., 2009; 
Lohrum et al., 2003; Zhang et al., 2003). The importance of the nucleolus in p53 
activation has also been highlighted by the observation that the nucleolar protein 
nucleophosmin is released from the nucleolus upon DNA damage, binds to p53 and 
mediates p53 stabilization (Colombo et al., 2002). 
Cells at the centre of an expanding tumour need to develop mechanisms to survive to 
hypoxia, a condition shown to activate the p53 apoptotic response through a 
mechanism involving ATR, HIF1α and VHL (Liu et al., 2007; Roe et al., 2006). 
In addition to acute insults, the p53 pathway can respond also to a variety of milder, 
constitutive stresses such as the generation of ROS by normal metabolism (Vousden 
and Ryan, 2009). Indeed, low levels of p53 regulate the activation of a set of 
antioxidant target genes that promotes repair of ROS induced damages and enhances 
cell survival. In this way, p53 exerts its tumour suppressive function by decreasing the 
incidence of genetic alterations even contributing to longevity of the organism 
(Sablina et al., 2005). 
Many other stresses that would result in a loss of fidelity in the cellular duplication 
process have recently been shown to cross with the p53 pathway (Vousden and 
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Prives, 2009; Vousden and Ryan, 2009). Heat and cold shock (Ohnishi et al., 1998a; 
Ohnishi et al., 1998b), presence of denaturated proteins, microtubule disruption and 
depletion of ribonucleotide-phosphate pool in the cell (Khan et al., 2000), spindle 
damage leading to faulty chromosomal segregation (Lanni and Jacks, 1998), nitric 
oxide production associated with infections and inflammation (Hofseth et al., 2003), 
all activate the p53 pathway and its downstream effects. 
 
 
Tumour suppressor activities of p53 
 
The outcomes triggered by the activation of the p53 pathway can be quite different, 
such as induction of reversible cell cycle arrest, DNA repair, senescence and 
apoptosis. These different outcomes depend on the cell type: in primary fibroblasts 
p53 activation is usually associated with cell cycle arrest (Di Leonardo et al., 1994; 
Kuerbitz et al., 1992), whereas in hematopoietic cells (e.g., thymocytes) it generally 
results in apoptosis (Lowe et al., 1993). Moreover, even within a particular cell type, 
the p53 pathway response is affected by many factors such as nature, duration and 
intensity of the stimuli and by the myriad of protein partners that modulate its stability 
and activity. All together these factors contribute to the regulation of the outcomes of 
the p53 pathway activation both in physiological and pathological conditions (Levine 
and Oren, 2009; Murray-Zmijewski et al., 2008; Vousden and Prives, 2009; Vousden 
and Ryan, 2009). 
 
Cell cycle arrest 
The activation of the p53 pathway can induce cell cycle arrest mostly promoting the 
induction of three critical target genes: p21, 14-3-3σ and GADD45 (el-Deiry et al., 
1993; Hermeking et al., 1997; Kastan et al., 1992). The cyclin-dependent kinase 
inhibitor p21Waf1/Cip1 has been the first identified transcriptional target of p53 (el-Deiry 
et al., 1994; el-Deiry et al., 1993). Upon p53 activation, p21 increased levels result in 
cell cycle arrest in G1 phase due to inhibition of cyclinA/CDK2, cyclinE/CDK2 and 
cyclinD/CDK4 (Harper et al., 1993). p21 was demonstrated to participate also in the 
G2/M arrest after DNA damage, presumably by blocking PCNA function at 
replication forks (Ando et al., 2001; Bunz et al., 1998). However, the p53-induced G2 
arrest is mostly mediated by the activation of other two genes, i.e. GADD45 and 14-3-
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3σ (Hermeking et al., 1997; Kastan et al., 1992). 14-3-3σ prevents nuclear import of 
cyclin B1 and CDC2 through their sequestration in the cytoplasm (Chan et al., 1999), 
whereas GADD45 destabilizes CDC2/cyclinB complexes, and these two processes 
cooperate to prevent initiation of mitosis (Jin et al., 2002; Zhan et al., 1999; Zhan et 
al., 1994). 
 
DNA-damage repair 
Part of the tumour suppressor function of the p53 pathway is exerted by preventing 
propagation of deleterious mutations arising from DNA damage. Two mismatch 
repair genes (MLH1 and PMS2) have been recently shown to be responsive to p53 
activation after DNA-damage (Chen and Sadowski, 2005). In addition, a direct 
participation of p53 protein in DNA repair was suggested by a number of biochemical 
observations. For instance, the C-terminal 30 amino acids of p53 were shown to 
recognize several DNA damage related structures, such as DNA ends, gaps, and 
insertion/deletion mismatches (Bakalkin et al., 1995; Jayaraman and Prives, 1995; 
Lee et al., 1995). Furthermore, numerous reports on physical and functional 
interactions further strengthened the proposal of a direct role of p53 in nucleotide 
excision repair (NER), base excision repair (BER), and double-strand break (DSB) 
repair (Albrechtsen et al., 1999; Bertrand et al., 2004). It has been suggested that p53 
may function in NER by facilitating access to chromatin to the repair machinery, thus 
favouring DNA repair (Rubbi and Milner, 2003b). p53 is also directly involved in 
inhibiting homologous recombination (HR) in response to replication fork stalling 
(Janz and Wiesmuller, 2002; Saintigny and Lopez, 2002) and, consistently, p53 
prevents the accumulation of DSBs at stalled-replication forks (Kumari et al., 2004; 
Squires et al., 2004). When DNA replication is blocked, p53 becomes phosphorylated 
on Ser15 and associates with key enzymes of HR (Linke et al., 2003; Restle et al., 
2005; Sengupta et al., 2003; Zink et al., 2002). 
 
Senescence 
Several lines of evidence suggest that the p53 tumour suppressor activity can be 
mediated by the induction of senescence both in vitro and in vivo (Chen et al., 2005b; 
Collado et al., 2005; Schmitt et al., 2002; Serrano et al., 1997; Ventura et al., 2007; 
Xue et al., 2007). Senescence is a cellular phenotype characterized by irreversible 
arrest of cell growth accompanied by a characteristic set of morphological changes in 
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the cell (Zuckerman et al., 2009). It can be triggered by the shortening of telomeres 
due to normal proliferation (replicative senescence) or by different exogenous or 
endogenous acute and chronic stimuli (telomere-independent or premature 
senescence), like oxidative stress (Chen et al., 2000), mitogenic oncogene 
overexpression (Ras, Raf) (Ferbeyre et al., 2002; Serrano et al., 1997), loss of tumour 
suppressor genes (PTEN) (Chen et al., 2005b) or supra-physiological mitogenic 
signals (overexpressed MAPK or E2F1) (Dimri et al., 2000; Lin et al., 1998). In both 
replicative and premature senescence a key role is mediated by tumour suppressor 
pathways involving p53 and p16-pRB, as demonstrated by a general resistance of 
human cells to multiple senescence-inducing stimuli upon loss of p53 and pRB 
function (Dimri et al., 2000; Serrano et al., 1997). 
DNA-damage response (DDR) is crucial for initiating both replicative and premature 
senescence: a common trigger is the occurrence of double strand breaks caused by 
telomere erosion or by oncogene activation through DNA hyper replication (Bartkova 
et al., 2006; d'Adda di Fagagna et al., 2003; Di Micco et al., 2006; Herbig et al., 2004; 
Takahashi et al., 2006). Consistently, in models of cellular senescence induced by 
DNA damaging agents causing double strand breaks, ATR/ATM mediates the 
activation of cell cycle checkpoints via Chk1/Chk2 and p53, with the participation of 
p21, p16 and Rb (Itahana et al., 2004; Itahana et al., 2001). 
While the upstream signals that trigger the activation of the p53 pathway in 
senescence are well established, much less is known on the actual mechanisms that 
contribute to this outcome. p21 is a crucial transcription target in mediating p53-
induced senescence and, in particular, at early phases p21 levels are transiently 
elevated and later gradually fall (Serrano et al., 1997). Instead, p16 levels rise in later 
passages (Alcorta et al., 1996; Stein et al., 1999). This suggests that p53 activity is 
crucial for the onset of senescence at least by inducing p21 in the first moments after 
the stimulus, while the permanent growth arrest is then maintained by p16 expression. 
Some key p53 regulators involved in senescence have been identified. For example, 
PML is up-regulated upon oncogenic Ras expression and induces senescence in a 
p53-dependent manner by promoting p53 acetylation at Lys-382 by p300 in the 
nuclear bodies (NBs) (Pearson et al., 2000; Webley et al., 2000). On the contrary, the 
deacetylase SIRT1, which also co-localizes in PML NBs, inhibits PML- and p53- 
induced senescence by deacetylating p53 (Langley et al., 2002). 
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Apoptosis 
According to cell type, inducing stress and extracellular environment, activation of 
p53 may result in apoptosis rather than cell cycle arrest. p53 contributes to apoptosis 
by transactivating a number of genes belonging in the Bcl2 family, such as Bax, Bid, 
Puma, Noxa, p53AIP1 (Miyashita and Reed, 1995; Nakano and Vousden, 2001; Oda 
et al., 2000a; Oda et al., 2000b; Sax et al., 2002) and repressing the anti-apoptotic 
genes Bcl2 and Bcl-xL (Miyashita et al., 1994a; Miyashita et al., 1994b). All these 
proteins are involved in permeabilization of the mitochondrial outer membrane and in 
release of cytocrome c (Vousden, 2005). Recently, it has emerged that the p53 
pathway can promote apoptosis without the requirement of p53 transcriptional 
activity. Indeed, p53 is able to localize to mitochondria, where it directly binds and 
inhibits Bcl2 and Bcl-xL, inducing release of cytochrome c (Mihara et al., 2003). 
Interestingly, the binding region of these two anti-apoptotic factors is p53 DNA 
binding domain, implying that mutant p53 proteins, which bear structural mutations 
in this region, may take advantage from the loss of these interactions. At the 
mitochondria, p53 interacts also with the pro-apoptotic factor Bak, promoting its 
oligomerization to form a transmembrane pore for the release of cytochrome c from 
mitochondria. Formation of the p53-Bak complex causes dissociation of Bak from the 
anti-apoptotic protein Mcl1 (Leu et al., 2004). Notably, a crosstalk between p53 
functions at the mitochondria and its transcriptional activity has been described. Upon 
stresses inducing p53 stabilization and activation, p53 induces the transcription of 
Puma, which releases cytoplasmic p53 from the inhibitory interaction with Bcl-xL, 
thus allowing it to directly activate Bax (Chipuk et al., 2005). 
 
 
Regulation of p53 levels and activities 
 
Given its potent growth suppressive activity, improper activation of p53 must be 
avoided in growing cells and this is obtained by precise mechanisms that control its 
stability and activity. When cells undergo stress, p53 stability, promoter recruitment 
and transcriptional activity are induced by means of multiple post-translational 
modifications and by interaction with activators and inhibitors (Kruse and Gu, 2009). 
These include proteins that enhance the translation of p53 mRNA, that modify p53 for 
both stabilization and transcriptional activation, that reverse these modifications or 
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that alter its sub cellular localization. Rather than simply leading to its rapid 
activation, all these events finely modulate p53 functions, allowing it to adapt and to 
coordinate appropriate responses to specific stimuli. 
 
Regulation of p53 transcription and translation 
For a long time, the regulation of p53 abundance has been associated only to its 
stabilization, nevertheless, relatively recently the modulation of p53 mRNA 
transcription and translation have also been shown to play a role in determining p53 
expression levels. Indeed, despite p53 mRNA levels were originally reported to be 
almost unaffected by several stresses (Giaccia and Kastan, 1998), p53 transcription 
was demonstrated to be regulated by BCL6 (Phan and Dalla-Favera, 2004), HOXA5 
(Raman et al., 2000) and CTCF (Phillips and Corces, 2009) in particular cellular 
contexts. 
p53 translation can be regulated by factors able to bind the 5’UTR and 3’UTR 
secondary structures of the p53 mRNA, that were demonstrated to play an intrinsic 
important role in negative auto-regulation of p53 mRNA translation (Fu and 
Benchimol, 1997; Fu et al., 1996). Acting on the 5’UTR, p53 translation is modulated 
in response to DNA damage positively by the ribosomal protein L26 (Ofir-Rosenfeld 
et al., 2008) and negatively by nucleolin (Takagi et al., 2005). Among the factors that 
bind to p53 3’UTR Hu antigen R (Mazan-Mamczarz et al., 2003) and Wig-1 (Vilborg 
et al., 2009) enhance p53 translation, while the thymydilate-synthase inhibits the 
translation of p53 mRNA (Ju et al., 1999). 
Recently it has emerged a new level of fine regulation of p53 expression by miRNAs 
as a post-transcriptional control: miR-125b, a brain-enriched miRNA, and miR-30 
family were demonstrated to negatively regulate p53 protein levels by acting on p53 
3’UTR (Le et al., 2009; Li et al., 2010). 
 
Regulation of p53 stability 
Regulation of p53 abundance occurs mainly at the protein level: in physiological 
conditions, p53 levels are maintained low thanks to efficient degradation mediated by 
the ubiquitin-proteasome system. Master regulator of p53 stability is its downstream 
target Mdm2, whose E3 ubiquitin ligase activity establishes a negative feedback loop 
(Wu et al., 1993), leading to attenuation of p53-mediated response under conditions of 
transient DNA damage (Rinaldo et al., 2007). The relevance of Mdm2 regulation on 
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p53 function is underscored by the phenotype of Mdm2 knockout mouse, whose 
embryonic lethality is rescued by simultaneous absence of p53 (Jones et al., 1995; 
Montes de Oca Luna et al., 1995). Mdm2 binds p53 within the N-terminal domain and 
mediates ubiquitylation on six Lys residues (370, 372, 373, 381, 382 and 386) within 
p53 C-terminal domain (Fang et al., 2000). Depending on its relative abundance with 
respect to p53, Mdm2 can catalyze either mono- or poly-ubiquitylation of p53, 
leading to nuclear export and translocation to mitochondria or intranuclear 
proteasomal degradation, respectively (Li et al., 2003; Marchenko et al., 2007). 
High levels of Mdm2 were found to accelerate tumour formation (Bond et al., 2004). 
In particular, a single nucleotide polymorphism at nucleotide 309 of intron 1 
(SNP309) increases recruitment of the transcriptional activator Sp1, resulting in 
higher Mdm2 levels, subsequent attenuation of the p53 pathway and earlier formation 
of sporadic soft tissue sarcoma (Bond et al., 2004). 
Furthermore, Mdm2 is able to catalyze the conjugation of NEDD8, a small protein 
similar to ubiquitin, to p53 in three Lys residues (370, 372 and 373) and to mono-
ubiquitylate histones, thereby inhibiting p53 transcriptional function (Xirodimas et al., 
2004). 
A complex role in the p53-Mdm2 loop is played by the Mdm2-related protein Mdmx 
(known as Mdm4 in mouse), which, although lacking ubiquitin ligase activity on its 
own, has been reported to complex with Mdm2 and stimulate its E3 activity towards 
p53, thus maintaining p53 at low levels under normal conditions (Linares et al., 
2003). Consistently, Mdmx knockout embryos die during early development and this 
can be rescued by concomitant deletion of p53, as in the case of Mdm2-/- mice (Parant 
et al., 2001). In addition to promote p53 ubiquitylation, Mdmx may also bind to p53 
N-terminus, thus directly repressing its transcriptional activity (Bergamaschi et al., 
2005). Aberrant expression of Mdmx was reported contribute to tumour development, 
and, indeed, Mdmx amplification and/or overexpression occurs in different tumours 
(Danovi et al., 2004). 
p53 ubiquitylation by Mdm2 is affected by several proteins. Two of them improve 
this process: gankyrin that increases the ubiquitin-ligase activity of Mdm2 
(Higashitsuji et al., 2005) and the transcription factor Yin Yang 1(YY1) that promotes 
p53 degradation by stabilizing the p53-Mdm2 complex (Sui et al., 2004). On the other 
hand, the tumour suppressor p14(ARF) is a pivotal positive regulator of p53 stability 
being able to block Mdm2 catalytic activity in vitro and the poly-ubiquitylation of 
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p53 in vivo (Brooks and Gu, 2004). p14(ARF), together with the other tumour 
suppressors p15(INK4B) and p16(INK4A), is a transcript variant of the CDKN2A 
locus and activates p53 response upon expression of activated oncogenes, such as 
Ras, Myc, and β−catenin (Damalas et al., 1999; Lin and Lowe, 2001). ARF is able to 
interfere also with the interaction of Mdm2 with YY1 and inhibits the activity of 
another E3-ubiquitin ligase of p53, ARF-BP1/Mule (Chen et al., 2005a). 
During the last decade, many others p53 E3-ubituitin ligases have been described 
(Lee and Gu, 2010). Among them, Pirh2 and COP1 are, like Mdm2, p53-inducible 
genes that participate in a comparable auto regulatory negative feedback loop (Dornan 
et al., 2004; Leng et al., 2003). 
Another route to degradation for p53 is mediated by the ubiquitin ligase CHIP 
(chaperone-associated ubiquitin ligase), which has been shown to poly-ubiquitinate 
p53 upon transient binding to HSP90 and HSP70. This mechanism might contribute 
to maintaining low levels of p53 under physiological conditions as CHIP depletion 
significatively augment p53 basal levels (Esser et al., 2005). Notably CHIP has been 
recently shown to play a role in mutant p53 ubiquitin-mediated degradation (Muller et 
al., 2008). 
p53 ubitiquitylation can be reversed by the deubiquitylating enzyme HAUSP (herpes 
associated ubiquitin-specific protease, also known as USP7), which can stabilize and 
activate p53 by removing ubiquitin moieties from its C-terminus, thus counteracting 
Mdm2 function (Li et al., 2002). Moreover, HAUSP is involved in rapid 
deubiquitylation of p53 in mitochondria, thus generating the apoptotically active non-
ubiquitylated p53 (Marchenko et al., 2007). 
An important role in modulating p53 localization, stability and functions, seems to be 
played also by USP10, a recently identified cytoplasmic ubiquitin-specific protease, 
that specifically deubiquitylates p53, inhibiting Mdm2-induced p53 nuclear export 
and degradation (Yuan et al., 2010). 
In addition to ubiquitin-conjugation, it has been shown that p53 can be degraded as 
well through an ubiquitin-independent mechanism. This pathway involves the 20S 
proteasome and is regulated by the NAD(P)H quinone oxido-reductase 1 (NQO1). 
The binding between NQO1 and p53 is regulated by NAD(P)H availability: 
NAD(P)H enhances p53-NQO1 binding, thus preventing p53 degradation by 20S 
proteasome (Asher et al., 2001; Asher et al., 2002). 
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Post-translational modifications 
p53 undergoes a great variety of post-translational modifications that influence its 
stability and its transcriptional activity. At the moment, it is known that more than 36 
different amino acids within p53 are modified: the actual pattern of post-translational 
modifications is complicated since there could be competition for the same residue, 
which can indeed be modified in different ways by different enzymes (figure 5). 
 
 
Figure 5. Overview of p53 post-translational modifications. The major sites of p53 phosphorylation 
(P), ubiquitination (Ub), and acetylation (Ac) are shown with the corresponding major modifying 
enzymes and signals. Furthermore, additional phosphorylation and acetylation sites, as well as major 
sites of methylation (Me), sumoylation (S), neddylation (N8), glycosylation (O-Glc), and ribosylation 
(ADP), are indicated. (Kruse and Gu, 2009). Other phosphorylations/dephosphorylations not described 
in the figure: Ser 215 phosphorylation by Aurora kinase A (Liu et al., 2004); Thr150 and Thr155 
phosphorylation by two COP9 signalosome-associated kinases, CK2 and protein kinase D (Uhle et al., 
2003); phosphorylation of Ser315 and Ser376 by GSK-3β (Pluquet et al., 2005; Qu et al., 2004); 
phosphorylation of Ser315 by the cyclinB-dependent kinase, p34(Cdc2) (Blaydes et al., 2001; Fogal et 
al., 2005) or by Aurora kinase A (Katayama et al., 2004); Ser392 phosphorylation by p38 MAPK or 
CK2 (Keller et al., 2001). Dephosphorylation of Ser-376 and Thr-55 (by PP2A) were also reported (Li 
et al., 2007; Waterman et al., 1998). 
 
Phosphorylation. Phosphorylation is the most extensively studied p53 post-
translational modification. Many kinases, including ATM, ATR, Chk1, Chk2, CK1, 
CK2, JNK, Erk, p38, Aurora Kinase A, GSK3β, HIPK2 and DYRK2, have been 
shown to phosphorylate p53 after DNA damage (Kruse and Gu, 2009; Vousden and 
Prives, 2009). So far, 17 phosphorylation/dephosphorylation sites on p53 have been 
detected in human cells following DNA damage (see figure 4). In addition, Thr55, 
Ser376 and Ser378 seem to be constitutively phosphorylated in unstressed cells (Gatti 
et al., 2000; Waterman et al., 1998). The redundancies observed in p53 
phosphorylation can be explained as a failsafe mechanism and also by the fact that 
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distinctive combination of phosphorylated residues could be required for further 
modifications, leading to maximal activation. Indeed, only a few p53 sites are 
phosphorylated by one specific protein kinase, as, for example, Ser6, Ser9 and Thr18 
by CK1 (Cordenonsi et al., 2007; Knippschild et al., 1997) and Thr18 by JNK 
(Buschmann et al., 2001). 
The best-characterized p53 phosphorylations are those in the N-terminus of the 
protein, in particular modifications that affect Ser15, Thr18, Ser20 and Ser46. Ser15 
is phosphorylated in an ATM-dependent manner in response to γ-irradiation (Banin et 
al., 1998; Waterman et al., 1998) and by ATR and p38 in response to UV light 
(Bulavin et al., 1999). After Ser15 phosphorylation, p53 is more transcriptionally 
active, also because of the increased interaction with the acetyl-transferase CBP 
(Lambert et al., 1998), and induces growth arrest and apoptosis (Fiscella et al., 1993; 
Shieh et al., 1997). Phosphorylation of other residues, including Thr18 and Ser20, 
which occurs later in the response to DNA damage, was shown to depend at least in 
part on initial phosphorylation at Ser15 and seems to interfere with the p53/Mdm2 
interaction, thus promoting p53 stabilization (Chehab et al., 1999; Dumaz et al., 1999; 
Unger et al., 1993). Phosphorylation of Ser46 can be performed by several kinases, as 
HIPK2 (D'Orazi et al., 2002; Hofmann et al., 2002), DYRK2 (Taira et al., 2007), 
AMPK (Okoshi et al., 2008), PKCδ (Yoshida et al., 2006) and p38 (Perfettini et al., 
2005). This phosphorylation mediates p53 selectivity in promoter recruitment, 
specifically promoting the induction of pro-apoptotic target genes (Bulavin et al., 
1999; D'Orazi et al., 2002; Oda et al., 2000a). 
It is likely that an ordered pattern and an interdependence of stress-induced 
modifications of p53 exist. However, the relevance and the precise role of 
phosphorylations on p53 and in its stabilization and activation remain controversial. 
While it seems likely that the complex network of stress-induced modifications of p53 
is important in generating a functional molecule, there is also evidence suggesting that 
p53 can be activated without these changes (Blattner et al., 1999; Fuchs et al., 1995). 
Further evidence pointing to a lack of requirement for post-translational modification 
in p53 stabilization comes from the use of small molecule inhibitors of the p53/Mdm2 
interaction, such as nutlins. These molecules do not induce phosphorylation of p53 
but this stabilized, unphosphorylated form of p53 is equally efficient at sequence-
specific DNA binding and the induction of apoptosis (Thompson et al., 2004). These 
controversial results do not mean however that phosphorylations on p53 are irrelevant 
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or do not occur in vivo, but it seems likely that the loss of one or even two or more of 
these modifications on p53 may be compensated quite easily (Toledo and Wahl, 
2006). 
 
Prolyl isomerization. Tightly connected to phosphorylation is the prolyl 
isomerization mediated by Pin1. In the case of p53, Pin1 plays a crucial role in 
transducing phosphorylation into conformational changes that affect p53 stability and 
function. Indeed, p53 stabilization and activation upon genotoxic stresses are 
impaired in the absence of Pin1 (Zacchi et al., 2002; Zheng et al., 2002). In particular, 
Thr81-Pro82 residues within the PRD are crucial for Pin1 to promote subsequent 
Chk2-dependent phosphorylation on Ser-20, which at the end induces dissociation of 
the p53/Mdm2 complex and favours p53 stabilization (Berger et al., 2005). 
Accordingly, mutations of Thr81-Pro82 have been reported in cancer patients with Li-
Fraumeni syndrome and sporadic breast tumours (Berger et al., 2005; Sun et al., 
1996). 
Pin1 is also involved in the regulation of p53 acetylation by p300, thus promoting p53 
transcriptional activity on its cognate promoters (Mantovani et al., 2007). 
Furthermore, after p53 phosphorylation on Ser46 triggered by cytotoxic stimuli, Pin1 
mediates p53 dissociation from the apoptosis inhibitor iASPP, thereby promoting cell 
death. Notably, in tumours bearing wild-type p53, expression of Pin1 and iASPP are 
inversely correlated, supporting the clinical relevance of these interactions 
(Mantovani et al., 2007). 
 
Acetylation/Deacetylation. p53 can be acetylated at several lysines by different 
histone acetyl-transferases (HATs) as p300/CBP and PCAF (p300/CBP-associated 
factor), which were shown to acetylate p53 in response to DNA damaging agents, 
such as UV- and γ-irradiation (Carter and Vousden, 2009). In detail, CBP and p300 
acetylate p53 at lysines within the C-terminal domain (Lys 370, 372, 373, 381 and 
382) (Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997). Moreover, Lys320 
and Lys305 in the nuclear localization signal are acetylated by PCAF and p300, 
respectively (Liu et al., 1999; Sakaguchi et al., 1998). Finally, the MYST family 
acetyl-transferases, hMOF and TIP60, were reported to acetylate p53 at Lys120 in the 
DBD (Berns et al., 2004). 
The role of acetylation in mediating p53 binding to DNA has been largely debated 
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and is still controversial. Indeed, a mouse expressing p53 lacking all the C-terminal 
lysines, showed no obvious abnormalities, with the mutant protein acting similarly to 
wild-type p53 in cell cycle arrest and apoptosis, thus suggesting that lysines in the 
CTD are not essential for p53 function, but instead fine-tune stress responses 
(Krummel et al., 2005). Conversely, the recently reported mutation of eight target 
lysines (8KR, in which are mutated the six C-terminal lysines and also Lys120 and 
Lys164 in the DBD) in p53, results in a p53 protein that cannot induce expression of 
several target genes, thereby failing to trigger cell cycle arrest or apoptosis (Tang et 
al., 2008). 
 
Other modifications affecting p53. In the last years several works described the 
identification of novel p53 modifications mostly on lysines, such as methylation, 
ubiquitylation, neddylation and sumoylation (Carter and Vousden, 2009). 
Methylation of p53 by methyl-transferases can occur at least at two different sites, 
reported to lead to opposing effects on p53 function. Indeed, while methylation at 
Lys372 by the methyl-transferase Set9 increases the stability of p53, restricting it to 
the nucleus and enhancing p53-dependent transcription (Chuikov et al., 2004), the 
methylation of Lys370, mediated by the methyl-transferase Smyd2, leads to 
repression of transcriptional activity (Huang et al., 2006). 
Three lysines targeted for ubiquitylation (Lys 370, 372 and 373) are also subjected to 
NEDDylation. The C-terminal glycine residue of the ubiquitin-like protein NEDD8 is 
covalently linked to p53 by Mdm2 thus inducing transcriptional repression 
(Xirodimas et al., 2004). 
Sumoylation consists in the addition of the small ubiquitin-like protein SUMO1 to the 
ε-amino group of lysine. In the case of p53, several reports have described the 
sumoylation of Lys386: however it is still controversial whether or not sumoylation 
positively modulates p53 transcriptional activity (Gostissa et al., 1999; Kwek et al., 
2001; Rodriguez et al., 1999). 
Recently, it has been described an interesting mechanism that controls p53 nuclear 
accumulation involving Poly(ADP-ribose) polymerase 1 (PARP-1) and the nuclear 
export receptor Crm1: PARP-1 was shown to poly(ADP-ribosyl)ate p53 on residues 
Glu258, Asp259 and Glu 271 (Kanai et al., 2007; Kumari et al., 1998), blocking the 
interaction between p53 and Crm1, thus resulting in nuclear accumulation of p53 
(Kanai et al., 2007). 
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Regulation by co-factors 
An increasing array of co-factors is known to influence the p53 pathway in different 
ways. Co-activator and co-repressors may affect p53 transcriptional activity by 
inducing modifications in chromatin surrounding the p53RE, by influencing p53 
loading on its target promoters, by mediating or preventing the assembly of the 
transcriptional machinery or by directing p53 activation towards a particular subset of 
target genes, thus leading to a specific response (Murray-Zmijewski et al., 2008). 
Key proteins that modulate the apoptotic functions of p53 at the transcriptional level 
are the highly conserved ASPP (Ankyrin repeats, SH3 domain, Proline-rich region 
Proteins, also known as Apoptosis Stimulating Proteins of p53) family members 
ASPP1, ASPP2 and the inhibitory iASPP. All the three proteins bind to p53 both on 
its DBD and PRD (Bergamaschi et al., 2003b; Bergamaschi et al., 2006; Samuels-Lev 
et al., 2001). ASPP1 and ASPP2 were shown to specifically enhance p53 ability to 
induce apoptosis but not cell cycle arrest and, accordingly, down-regulation of ASPP1 
and ASPP2 is a frequent event in human tumours bearing wild-type p53 (Samuels-
Lev et al., 2001). Instead, iASPP (inhibitory member of the ASPP family) is an 
oncoprotein that cooperates with Ras, E1A and E7 to transform cells in vitro 
(Bergamaschi et al., 2003b). Moreover, iASPP counteracts the effects of ASPP1 and 
ASPP2 by competing for binding to p53: depletion of iASPP expression increases 
p53-dependent apoptosis while its over-expression inhibits this process (Bergamaschi 
et al., 2003b; Bergamaschi et al., 2006). 
Other factors, as the hematopoietic zinc finger (Hzf) protein (Das et al., 2007), the 
specific PML isoform PML3 (Fogal et al., 2000) and the bRN3b protein (Budhram-
Mahadeo et al., 2006), boost p53 pro-apoptotic activities instead of cell cycle arrest 
by changing p53 chromatin loading on apoptotic and cell cycle p53 target promoters. 
On the contrary, bRN3a protein seems to favour cell cycle arrest (Budhram-Mahadeo 
et al., 2002; Hudson et al., 2005). 
A number of transcriptional co-activator and co-repressor complexes that bind p53 in 
cells possesses histone modifying activities suggesting that targeted chromatin 
remodelling may be important for p53 to function as a transcription factor. Indeed, 
p53-dependent changes in histone acetylation have been observed at the promoters of 
a number of p53 target genes and correlated with the role of CBP/p300 in regulating 
p53-dependent transcription (Espinosa and Emerson, 2001; Liu et al., 1999). In 
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further support of the importance of chromatin remodelling, several other proteins 
involved in this process were shown to have a role in the regulation of p53 
transcriptional activity, as the histone deacetylase HDAC1 (Lagger et al., 2003), the 
co-repressor mSin3a (Murphy et al., 1999), the ATP-dependent remodelling complex 
SWI/SNF (Lee et al., 2002), the oncoprotein MUC1 (Wei et al., 2005) and the human 
cellular apoptosis susceptibility protein (CAS/CSe1L) (Tanaka et al., 2007). 
Likely p53 post-translational modifications may provide the means for selective co-
regulators recruitment. This is also supported by the evidence of a correlation between 
particular post-translational modifications and specific cellular outcomes, as reported 
for the association of Ser46 phosphorylation with apoptotic response (D'Orazi et al., 
2002; Oda et al., 2000b) and Lys120 acetylation with selective activation of apoptotic 
genes (Sykes et al., 2006; Tang et al., 2006). 
 
Subcellular localization 
Being p53 primarily active as a transcription factor, its cellular compartmentalization 
is strikingly important. The nucleo-cytoplasmic translocation of p53 is tightly 
regulated during cell cycle (Shaulsky et al., 1990). The subcellular localization of p53 
is regulated by a nuclear localization signal (NLS) in its C-terminus and two nuclear 
export signals (NES), at the N-terminus (nNES) and at the C-terminus (cNES). It has 
been demonstrated that cNES is masked in the p53 tetramer, which increases the 
nuclear fraction of transcriptionally active protein (Stommel et al., 1999). 
Mdm2 is also involved in this aspect of p53 regulation, as it can indeed mediate p53 
nuclear export as a first step in the process of degradation (Freedman and Levine, 
1998; Honda et al., 1997). However nuclear export is not essential for p53 
ubiquitylation, since p53 proteins localizing exclusively to either the nucleus or 
cytoplasm can be ubiquitylated and degraded by Mdm2 (Yu et al., 2000). 
Furthermore, mono-ubiquitylation of p53 by Mdm2 promotes p53 translocation to 
mitochondria, where it subsequently undergoes rapid deubiquitylation by HAUSP 
becoming active in the induction of apoptosis (Marchenko et al., 2007). 
Beside Mdm2, another critical regulator in controlling p53 subcellular localization is 
Parc, a Parkin-like ubiquitin ligase, that forms a complex with p53 in the cytoplasm of 
unstressed cells, acting as a cytoplasmic anchor for p53 (Nikolaev et al., 2003). 
Accordingly, abnormal cytoplasmic localization of p53 was observed in a number of 
neuroblastoma cell lines, which can be sensitized to DNA damage response upon 
Introduction 
 32 
RNAi-mediated reduction of endogenous Parc (Nikolaev et al., 2003). 
Finally, p53 can be recruited to the nuclear bodies (NBs), subnuclear compartments 
also known as PML bodies, since PML is the factor leading their assembly. Although 
their function is not totally clear, NBs are dynamic multiprotein-complexes 
comprising numerous transient or permanently localized proteins (Bernardi and 
Pandolfi, 2007). Among NBs localized proteins, there are also p53 and many of its 
effectors, suggesting that NBs could provide a scaffold for the regulation of p53 post-
translational modifications (Borden, 2002; Guo et al., 2000; Zhong et al., 2000a; 
Zhong et al., 2000b). For instance, the co-localization of p53, CBP, and HIPK2 in 
PML NBs contributes to the regulated p53 phosphorylation of Ser46 by HIPK2 and 
acetylation by CBP in response to DNA damage (D'Orazi et al., 2002; Guo et al., 
2000; Hofmann et al., 2002). 
It has been reported that NBs are required for Ras-induced senescence through a 
mechanism involving p53 acetylation at Lys382 by CBP (Pearson et al., 2000). As 
already mentioned, SIRT1, a p53 deacetylase, also co-localises with acetylated p53 in 
NBs and seems to be involved in mediating cellular senescence (Langley et al., 2002). 
PML also protects p53 from Mdm2-mediated ubiquitylation and degradation by 
inducing the auto-phosphorylation and activation of Chk2 that consequently 
phosphorylates p53 on Ser20 (Yang et al., 2006). 
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3.2 Mutant p53 
 
Mutations in the TP53 gene are among the most common gene-specific alterations in 
human cancer. The frequencies of reported TP53 mutations vary considerably 
between cancer types, ranging from 10% in haematopoietic malignancies (Peller and 
Rotter, 2003) to 50–70% in ovarian (Schuijer and Berns, 2003), colorectal (Iacopetta, 
2003) and head and neck (Blons and Laurent-Puig, 2003) cancers. Whereas somatic 
TP53 mutations contribute to sporadic cancer, germline TP53 mutations cause a rare 
type of cancer predisposition known as Li-Fraumeni Syndrome (LFS), which is not 
associated with site-specific tumours, but rather with a variety of tumour types 
occurring at a relatively early age (Li and Fraumeni, 1969). 
Even if inactivation of the TP53 gene may be achieved through several types of 
mutations (missense and nonsense mutations or insertions/deletions of several 
nucleotides), missense mutations account for more than 70% of them (IARC TP53 
Database, www.p53.iarc.fr). As a consequence, in the vast majority of tumours with 
mutations in the TP53 gene, cells express a full-length mutant form of the protein, 
which differs from the wild-type counterpart in a single amino acid substitution. 
Both germline mutations and sporadic somatic mutations show the same distribution 
in the TP53 gene (Varley, 2003). Indeed, they are not randomly dispersed along the 
whole sequence, but are generally found in the region corresponding to the DBD of 
the protein (figure 6). 
 
 
Figure 6. The distribution of reported missense mutations along the p53 sequence. The six most 
common hotspot mutations are highlighted in yellow for DNA-contact mutations, green for locally 
distorted mutants and blue for globally denatured mutants. The domain architecture of p53 is aligned 
below. TA, transactivation domain; PR, proline-rich domain; DBD, DNA binding domain; Tet, 
tetramerization domain; Reg, carboxy-terminal regulatory domain. Data derived from the IARC TP53 
Database. 
 
As shown in figure 6, almost a third of all missense mutations arise in six “hotspot” 
codons (Hollstein et al., 1991; Petitjean et al., 2007). Most TP53 mutations can be 
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classified into two main categories according to their effect on the thermodynamic 
stability of the p53 protein (Bullock and Fersht, 2001). These two mutation categories 
are commonly referred to as “DNA‑contact” and “conformational” mutations. The 
first group includes mutations in residues directly involved in DNA binding, such as 
R248Q and R273H. The second group comprises mutations that cause local (such as 
R249S and G245S) or global (such as R175H and R282W) conformational 
distortions. 
 
 
Functional impacts of TP53 mutations 
 
The phenotypic effects of TP53 mutations can be classified into three non-mutually 
exclusive groups (figure 7). 
 
 
Figure 7. Schematic representation of the functional impacts of TP53 mutations. LOF (loss of 
function); DN (dominant-negative effects); GOF (gain of function). (Brosh and Rotter, 2009) 
 
First, most mutations observed in human tumours abrogate the tumour suppressor 
functions of the affected allele. This loss of function is due to reduction of p53 
binding to its consensus DNA sequence and, consequently, hampered transcriptional 
activation of p53 target genes (Kato et al., 2003). Although loss of function occurs 
among missense mutants, it is particularly relevant in truncating, splicing and 
nonsense mutations, as well as in gene deletions. If in the same cell also the remaining 
allele becomes mutated or is lost (loss of heterozygosity), such a cell will be totally 
deprived of anticancer protection by p53. 
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Second, most missense mutations also produce a full-length mutant p53 capable of 
inhibiting, to varying degrees, the function of the wild-type protein encoded by the 
second allele. This dominant-negative effect is achieved by oligomerization of 
mutant and wild-type proteins, forming a heterotetramer defective in sequence-
specific DNA binding (Milner and Medcalf, 1991; Milner et al., 1991). Hence, even if 
the wild-type allele is retained, the cell may be rendered practically devoid of wild-
type p53 functions through such a mechanism. 
Finally, several mutations were shown to confer mutant p53 with new functions that 
are independent of wild-type p53. Such activities, commonly described as mutant p53 
gain of function (GOF) can actively contribute to various aspects of tumour 
progression (figure 8). 
 
Figure 8. Selected oncogenic properties of mutant p53 and their underlying mechanisms. The 
inner circle (shaded blue) represents oncogenic phenotypes associated with the activities of mutant p53 
proteins. The outer circle depicts key mechanistic properties of p53 mutants that underlie the 
phenotypes listed in the inner circle. Each of the phenotypic effects can be attributed to almost each of 
the mechanistic properties; hence the inner blue circle can be freely rotated. (Brosh and Rotter, 2009) 
 
Cell transformation 
The first clue regarding mutant p53 gain of function was obtained in 1993, when it 
was shown that p53 mutants of both human and mouse origin, but not their wild-type 
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counterparts, can transform p53-null cells and endow them with an increased ability 
to form colonies in soft agar and tumours in mice (Dittmer et al., 1993). Accordingly, 
experiments performed knocking down mutant p53 in several human cancer cell lines, 
demonstrated that down-regulation of endogenous mutant p53 rendered those cells 
less tumorigenic (Bossi et al., 2006; Bossi et al., 2008). 
Mutant p53 was shown to cooperate with activated oncogenic Ras in transformation 
of primary mouse embryo fibroblasts (MEFs) (Lang et al., 2004). This property is due 
to the ability of different p53 mutants to bind and inactivate p53 family members, p63 
and p73 (Di Como et al., 1999; Gaiddon et al., 2001; Strano et al., 2000): indeed, in 
cells without mutant p53, both p63 and p73 prevent Ras-induced cell transformation 
by triggering senescence (Fang et al., 1999; Guo et al., 2009). 
Cooperation between mutant p53 and oncogenic Ras was described also in vivo by 
using mouse models of skin (Caulin et al., 2007), lung (Jackson et al., 2005) and 
pancreatic cancers (Hingorani et al., 2005). Such mice exhibited increased tumour 
formation, accelerated tumour progression and elevated rates of metastasis relative to 
their p53-null counterparts. 
 
Drug resistance and inhibition of apoptosis 
One distinctive feature of many p53 mutants is the ability to confer an elevated 
resistance to cells towards a variety of pro-apoptotic signals. This effect of mutant 
p53 was revealed for the first time by showing that mutant p53 could suppress cMyc-
induced apoptosis in leukemic cells (Lotem and Sachs, 1995). 
Interestingly, overexpression of various tumour-associated p53 mutants can render 
cells more resistant to killing by anticancer agents (Blandino et al., 1999; Li et al., 
1998; Matas et al., 2001), whereas knockdown of endogenous mutant p53 sensitizes 
cancer cells to killing by such molecules (Bossi et al., 2006; Wong et al., 2007). 
The mutant p53 ability to protect cells from chemotherapeutic drugs is largely due to 
its capability to inhibit p73 pro-apoptotic functions (Bergamaschi et al., 2003a). 
Accordingly, short peptides disassembling the mutant p53/p73 complex restore p73 
activity and re-sensitize cells harbouring mutant p53 to chemotherapy (Di Agostino et 
al., 2008). 
 
Genomic instability 
A connection between mutant p53 and increased genomic instability was 
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demonstrated by showing that human p53 mutants could disrupt normal spindle 
checkpoint control, leading to accumulation of cells with polyploid genomes 
(Gualberto et al., 1998). Additional manifestations of the enhanced genomic 
instability due to mutant p53 have been reported: higher mutation rates in the T-cell 
receptor of cells exposed to X-irradiation (Iwamoto et al., 1996), increased frequency 
of centrosome amplification and aberrant mitoses in mouse mammary epithelial cells 
(Murphy et al., 2000; Murphy and Rosen, 2000), as well as increased gene 
amplification in Saos2 cells (El-Hizawi et al., 2002). 
The existence of this connection was established also in vivo, as aneuploidy 
associated with aberrant centrosome amplification and nonreciprocal chromosome 
translocations without evidence of telomere erosion (Caulin et al., 2007; Hingorani et 
al., 2005). 
Mutant p53 enhances genomic instability through the inhibition of ATM-mediated 
cellular responses to double-stranded DNA breaks (Song et al., 2007). This is caused 
by the interaction between mutant p53 and the nuclease Mre11, a component of the 
Mre11-Rad50-NBS1 (MRN) complex, preventing recruitment to double-stranded 
DNA breaks. As binding of the MRN complex to such DNA breaks is required for 
optimal ATM activation, the presence of mutant p53 curbs signalling through this 
pathway and enables persistence of unrepaired DNA damage. 
In addition to this, mutant p53 can interfere with DNA repair by attenuating base 
excision repair (Offer et al., 1999) and by binding topoisomerase I, thus leading to 
aberrant homologous DNA recombination events and mutagenic DNA 
rearrangements (Albor et al., 1998; Restle et al., 2008). 
 
Cell migration and invasion 
Although p53 knockout mice are highly tumour prone, these lesions do not 
metastasize frequently nor generally display invasive pathology (Attardi and Jacks, 
1999). On the contrary, presence of mutant p53 leads to a marked increase in the 
incidence of highly metastatic carcinomas in various mouse models (Doyle et al., 
2010; Heinlein et al., 2008; Lang et al., 2004; Liu et al., 2000; Morton et al., 2010; 
Olive et al., 2004). Indeed, another aspect of mutant p53 gain of function that has 
recently emerged is its ability to drive cell migration and invasion (Adorno et al., 
2009; Dhar et al., 2008; Muller et al., 2009). This is achieved by two non-mutually 
exclusive mechanisms of inhibition of p63 anti-metastatic functions (figure 9). 
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Figure 9. Mutant p53 regulates cell migration and invasion by inhibiting p63. (A) Upon TGF-β 
induction, SMAD2 is phosphorylated and promotes binding of mutant p53 to p63, alleviating p63-
mediated suppression of Sharp-1 and Cyclin G2 to allow for cell migration and invasion. (Adorno et 
al., 2009) (B) p63 inhibits activation of RCP (through transcriptional targets that are currently 
unknown) to prevent α5β1 integrin and EGFR recycling to the plasma membrane. When mutant p53 is 
present, p63 activity is suppressed, resulting in enhanced RCP-driven recycling of α5β1 integrin and 
EGFR. This activates Rho and PKB/Akt to promote cell migration and invasion. (Muller et al., 2009) 
(Muller et al., 2011). 
 
Furthermore, mutant p53 can promote partial EMT-like transition via Slug or Twist 
(Kogan-Sakin et al., 2011; Wang et al., 2009), or by suppressing the anti-invasive 
gene CCN-5/WISP2 (Dhar et al., 2008). 
 
Alteration of gene expression 
Although two thirds of missense mutations in the DBD, including all “hotspot” 
mutations, abrogate the ability to recognize wild-type p53 response elements (Kato et 
al., 2003), modulation of gene transcription by mutant p53 is well documented and 
the list of mutant p53 target genes is constantly growing (Brosh and Rotter, 2009). 
However, a unifying mechanism for the selectivity of mutant p53 to certain genes is 
still missing owing to lack of consensus DNA sequence in the regulated genes and 
variability in the identity of genes affected by different p53 mutants. A possible 
explanation is the evidence that several p53 mutants, although defective in sequence-
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specific DNA binding, retain the ability to bind specific non-B DNA structures with 
high affinity, even if different mutants bind various DNA structures through distinct 
mechanisms and with different affinities (Gohler et al., 2005). Therefore, the 
specificity of mutant p53 to certain regulatory sequences is perhaps mediated by 
preferential binding to structural DNA motifs and not consensus sequences. 
For some mutant p53 target genes, it became clear that mutant p53 interacts with 
sequence-specific transcription factors, resulting in either augmentation or attenuation 
of their activity. Besides p63 and p73, the first two transcription factors shown to 
interact with mutant p53 were SP1 and ETS1 (Chicas et al., 2000; Sampath et al., 
2001), which also interact with wild-type p53. Interestingly, the pro-survival effects 
mediated by mutant p53 acting on Sp1 and ETS1 are the opposite compared to those 
obtained by their complexes with wild-type p53, suggesting that additional but 
distinct co-factors are recruited by mutant p53 and wild-type p53 (Kim and Deppert, 
2004). 
Similarly, the transcription factor NF-Y, which also interacts with wild-type p53, was 
demonstrated to bind to mutant p53. Conversely to wild-type p53, which recruits 
HDAC1 on the promoters of NF-Y target genes, mutant p53/NF-Y complex is 
associated to p300 upon adriamycin treatment, thus inducing their transcription (Di 
Agostino et al., 2006). This complex was proposed to support the growth promoting 
properties of mutant p53 as well as the chemoresistance of some mutant p53 bearing 
tumours (Aas et al., 1996; Bergh et al., 1995; Lu and El-Deiry, 2009). 
The most recent example of mutant p53 interacting transcription factor is vitamin D 
receptor (VDR). By performing ChIP-on-chip analysis, the VDR response element 
was found to be over-represented in promoters bound by mutant p53 R175H. Mutant 
p53 is indeed recruited on VDR-regulated genes and modulates their expression, thus 
converting vitamin D receptor into an anti-apoptotic factor (Stambolsky et al., 2010). 
 
Regulation of mutant p53 stability and activity 
 
In contrast to the plethora of information available in the case of wild-type p53, the 
regulation of mutant p53 stability and activity and the status of its post-translational 
modifications have yet to be characterized in detail (Brosh and Rotter, 2009). 
High levels of mutant p53 are generally found in tumours (Bartek et al., 1991), 
nonetheless mutation by itself is not sufficient to explain the greater stability of 
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mutant p53 compared to its wild-type counterpart. Indeed, several murine and 
zebrafish models, that are homozygous for mutant p53, display no stabilization of the 
protein in normal tissues but have high levels in tumours arising in these backgrounds 
(Lang et al., 2004; Lee et al., 2008; Olive et al., 2004). Similarly, mutant p53 does not 
accumulate in normal tissues from patients with Li-Fraumeni syndrome, contrary to 
what occurs in tumours from these same patients (Soussi and Beroud, 2001). 
Importantly, Mdm2–/– mice harbouring knock-in TP53 mutants accumulate mutant 
p53 also in some normal tissues (Terzian et al., 2008), thus indicating that Mdm2, 
besides acting on wild-type p53, is a pivotal regulator of mutant p53 stability in vivo. 
In vitro biochemical experiments have demonstrated that mutant p53 is a substrate of 
another ubiquitin ligase that targets also wild-type p53: C-terminus of HSP70-
interacting protein (CHIP) (Esser et al., 2005; Lukashchuk and Vousden, 2007). 
CHIP-mediated ubiquitylation of mutant p53 is counteracted by the chaperone 
HSP90, which binds to mutant p53 increasing its stability (Esser et al., 2005; Nagata 
et al., 1999). Since HSP90 is frequently over-activated in tumours (Kamal et al., 
2003), the dependency of mutant p53 on HSP90 may partly account for its specific 
accumulation in tumours and underlie the therapeutic potential of HSP90 inhibitors 
(Solit and Rosen, 2006). 
Mutant p53 can be degraded also in a ubiquitin-independent way by proteasome 20S, 
but this process can be inhibited by its interaction with NQO1, which thereby 
represents an important positive modulator of mutant p53 stability (Asher et al., 
2003). 
Several evidences from in vivo studies highlighted that elevated mutant p53 protein 
levels and its phosphorylation status, increased by altered signalling pathways in 
tumour cells, are associated with mutant p53 gain of function (Song et al., 2007; 
Soussi and Beroud, 2001; Terzian et al., 2008). This supports the notion that stress 
signalling could activate mutant p53 through mechanisms similar to those required to 
stimulate wild-type p53 (Song et al., 2007; Terzian et al., 2008). To investigate and 
dissect how oncogenic signalling triggers mutant p53 activities, we focused on factors 
that might link cancer-related signalling with mutant p53 functions and we found that 
the prolyl isomerase Pin1 is crucial in this mechanism. 
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3.3 The prolyl isomerase Pin1 
 
Post-translational modifications of proteins are important signalling mechanisms 
involved in many cellular pathways, such as those controlling cell cycle, transcription, 
DNA repair, cell survival and differentiation. In particular, phosphorylation of 
proteins on serine or threonine residues that immediately precede a proline (pS/T-P), 
so-called Pro-directed phosphorylation, is a central signalling mechanism that has 
been shown to play an important role in regulating different biological processes and 
pathological conditions (Lu and Zhou, 2007). S/T-P motifs are exclusive 
phosphorylation sites for a large number of Pro-directed kinases that play essential 
roles in signal transduction and cell cycle progression. These include all cyclin-
dependent kinases (CDKs), as well as most of the mitogen-activated protein kinases 
(MAPKs) and glycogen synthase kinase 3β (GSK-3β). Importantly, the ability of 
these enzymes to phosphorylate the substrates strictly depends on the presence of the 
proline residue: its point mutation abolishes phosphorylation and typically disrupts 
phosphorylation signalling. 
Peptide bonds preceding proline residues have the unique property of existing in two 
completely distinct isomers, cis and trans, in folded proteins and therefore can 
provide a potential backbone switch in the polypeptide chain that is controlled by 
cis/trans isomerization around the peptidyl-prolyl bond (Hunter, 1998). This 
intrinsically rather slow conversion can be catalyzed by peptidyl-prolyl isomerases 
(PPIases), which play an important role in protein folding or refolding (Hunter, 1998). 
These enzymes comprise three structurally distinct subfamilies: the cyclophilins, 
FK506-binding proteins (FKBP) and the parvulins (Galat, 2003). Pin1, which is a 
parvulin, is the only known human isomerase specifically regulating the conformation 
of Pro-directed phosphorylation sites, thus providing an additional level of protein 
regulation (Lu et al., 1996; Ranganathan et al., 1997; Yaffe et al., 1997). 
 
 
Functional domains of the Pin1 protein 
 
The human Pin1 gene maps to the chromosome 19p13 and encodes an 18kDa protein 
of 163 amino acids. From a functional point of view, it is composed of two domains: 
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an amino terminal WW domain (amino acids 1– 39) and a carboxy-terminal PPIase 
domain (amino acids 45–163), which are separated by a short flexible linker region 
(figure 10). 
 
Figure 10. Pin1 structure and function. Schematic representation of the two functional domains of 
Pin1 (the interacting WW region and the PPIase catalytic region) and the structural consequence on the 
backbone of the target protein due to Pin1 isomerase activity (Yeh and Means, 2007). 
 
The N-terminal WW region is characterized by two conserved tryptophan residues 
(Sudol et al., 2001) and is organized in a three-stranded antiparallel β-sheet (Sudol 
and Hunter, 2000). It mediates the interaction with the substrates on pS/T-P sites, 
which cannot be bound by any other isomerase (Ranganathan et al., 1997; Yaffe et al., 
1997). As a consequence of the interaction, the WW domain targets the Pin1 catalytic 
domain close to its substrates, so that the PPIase domain can isomerize specific pS/T-
P motifs and catalytically induce conformational changes (Lu et al., 1999; Zhou et al., 
2000). The residues in the Pin1 catalytic pocket responsible for the phosphorylation 
specificity are Lys63, Arg68 and Arg69, a basic triad forming an anionic recognition 
site required to select the negative charge on the amino acid preceding the proline 
residue (Zhou et al., 2000). 
 
 
Regulation of Pin1 activity 
 
Pin1 expression and function are tightly regulated by multiple mechanisms under 
normal growth conditions and during the cell cycle. Its expression can be induced by 
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growth signals acting through the E2F family of transcription factors (Ryo et al., 
2002). As a consequence, Pin1 levels changes during cell cycle progression in normal 
cells, while they are constitutively increased in transformed cells (Bao et al., 2004). 
Pin1 activity can be affected by an inhibitory phosphorylation on Ser 16: this residue 
is at the centre of the pS/T-P binding pocket of the WW domain and, once 
phophorylated, Pin1 interaction with its substrates is inhibited (Yaffe et al., 1997). 
Interestingly, Pin1 seems to be hypophosphorylated in breast cancer, suggesting that 
Pin1 could be overexpressed and also activated during oncogenesis (Wulf et al., 
2005). 
Pin1 can be phosphorylated also on Ser65 by Plk1 (Eckerdt et al., 2005). Although 
being near the catalytic pocket, this phosphorylation does not affect Pin1 isomerase 
activity but rather is linked to its stability. Indeed, inhibition of Plk1 activity enhances 
Pin1 ubiquitylation, while substitution of Ser65 with a Glu residue reduces 
ubiquitylation thus increasing the protein stability (Eckerdt et al., 2005). 
 
 
Pin1 animal models 
 
Pin1 was discovered through a yeast two-hybrid screening designed to identify 
proteins that interact with never in mitosis gene A (NIMA), an essential mitotic 
kinase in A. nidulans (Lu et al., 1996). The overexpression of NIMA in yeast (or cells 
of any eukaryote) is lethal, since it induces premature chromosome condensation 
followed by cell death. The overexpression of Pin1 reverts this phenotype, thus 
suggesting a role as a regulator of mitosis (Lu et al., 1996). Indeed, Pin1 orthologue in 
S. cerevisiae is the mitotic protein ESS1, whose deletion induces terminal mitotic 
arrest (Hanes et al., 1989). Additional evidence obtained in X. laevis supports a role 
for Pin1 in mitosis, as the addition of Pin1 to Xenopus egg extracts leads to the 
inhibition of mitotic entry (Crenshaw et al., 1998; Winkler et al., 2000). 
Although Pin1 is highly evolutionarily conserved and is essential in S. cerevisiae, C. 
albicans and A. nidulans, it is not an essential protein in metazoans such as D. 
melanogaster or M. musculus (Fujimori et al., 1999; Maleszka et al., 1996). The 
absence of dodo, the Pin1 homologue in Drosophila, results in no obvious phenotypic 
consequences, but developmental defects in the dorsal-ventral patterning of the egg 
chamber (Hsu et al., 2001; Maleszka et al., 1996). 
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Knockout mice for Pin1 gene have been produced in two different backgrounds. The 
first model, which was obtained in a mixed background (129SvJae/C57BL/6), 
displays tissue defects linked to aging. Along with decreased body weight and 
testicular atrophy, the most dramatic alterations involve retina and mammary gland. 
Indeed, Pin1-/- mice show dramatic impairments in cell survival and proliferation in 
the retina. Moreover, it is very clear and striking that in pregnant Pin1-/- female, 
mammary epithelia cells fail to undergo massive proliferation in the development of 
alveolar structures and ductal side branching (Liou et al., 2002). 
In the model realized in C57BL/6 background, both male and female Pin1-null mice 
display a reduced number of germ cells owing to impairment in primordial germ cell 
(PGC) expansion, thereby causing to a profound decrease in fertility (Atchison et al., 
2003). Although Pin1 depletion was previously reported to lead to apoptosis or 
mitotic arrest, neither of these defects occurred in the PGCs. Instead, the PGCs had a 
marked increase in duration of the cell cycle owing to a prolonged G1–S transition, 
thus implying a critical role for Pin1 in controlling this part of the cell cycle (Atchison 
et al., 2003). 
 
 
Biological functions of Pin1 
 
Due to the great number of its protein targets, Pin1 can be involved in many cellular 
processes, such as cell cycle control, transcription, chromatin remodelling and DNA 
damage response (figure 11), so that in physiological conditions it can act as an 
important modulator of different signalling pathways (Lu, 2004). 
Since its discovery (Lu et al., 1996), Pin1 was associated with cell cycle control. 
Progression through the several phases of the cell cycle is driven by the timely 
activation and inactivation of different Pro-directed cyclin-dependent kinases (Nigg, 
2001). Notably, Pin1 has been shown to be a key regulator of mitotic events by acting 
on numerous substrates, such as CDC25C and WEE1, which are the activating 
phosphatase and inhibitory kinase of cyclin B–CDC2, respectively (Okamoto and 
Sagata, 2007; Zhou et al., 2000). In addition, Pin1 stabilizes EMI1 (early mitotic 
inhibitor-1), which prevents the anaphase-promoting complex (APC) from acting on 
cyclin A and B during S and G2 phases, allowing the coordination of S and M phases 
(Bernis et al., 2007). 
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Figure 11. The plethora of Pin1 functional targets. PIN1 can lead to changes in cell-cycle 
progression through the regulation of proteins such as cyclin D1, cyclin E, Myc, Fos, Jun and CDC25, 
and/or influence checkpoint function through p53 and p73. Pin1 also regulates proteins involved in 
apoptosis, such as p53, p73, Bcl2 and its extra long isoform. Some of these effects occur as a result of 
protein activation, such as Raf1, protein stabilization, as shown for cyclin D1, β-catenin and NF-κB, or 
protein degradation, such as Jun, Myc and cyclin E. Finally, Pin1 can affect the transcription or 
transcriptional activation of specific genes such as cyclin D1, Fos, Jun, RARα and NCOA3. (Yeh and 
Means, 2007) 
 
Pin1 was found to localize to chromatin in the G2/M phase by interacting with 
topoisomerase IIα (Xu and Manley, 2007). Moreover, purified Pin1 and cyclin B–
CDC2 kinase are by themselves sufficient to induce chromatin condensation in 
Xenopus extracts, presumably by increasing phosphorylation of topoisomerase IIα by 
cyclin B–CDC2 and promoting its binding to DNA (Xu and Manley, 2007). 
Pin1 has a pivotal role also in the G1/S transition for the coordination of centrosome 
duplication and DNA synthesis. Indeed, Pin1 localizes to centrosomes and its ablation 
drastically delays centrosome duplication. On the contrary, Pin1 overexpression 
induces centrosome amplification and chromosome aneuploidy (Suizu et al., 2006). 
Critical for the correct completion of the G1/S transition is Pin1 promoted cyclin E 
degradation mediated by the FBXW7 E3 ligase (van Drogen et al., 2006; Yeh et al., 
2006). The Pin1 binding motif and FBXW7 as E3 ligase are required also for 
ubiquitylation and degradation of c-Myc (Yeh et al., 2004). 
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Linked to role of Pin1 in cell cycle control is its modulation of the RNA polymerase 
II structure and function. This prolyl isomerase is able to bind to the C-terminal 
domain of the RNA polymerase II, thus affecting its dynamic association with 
specific genes during the cell cycle. Indeed, Pin1 promotes its recruitment in the 
promoters of transcribed genes in S phase, while causes its disassociation in M phase 
(Xu et al., 2003; Xu and Manley, 2007). 
Many kinases activated in response to different stresses are Pro-directed kinases, 
which include JNK, p38 and ERKs (Karin and Gallagher, 2005; Roux and Blenis, 
2004). Pin1 has been shown to regulate the function of several key proteins involved 
in various cellular stress responses. For example, upon genotoxic insults, Pin1 binds 
to phosphorylated p53 and p73 and increases their stability and transcriptional 
activity, thereby maintaining DNA damage checkpoints and allowing apoptosis by 
enhancing pro-apoptotic gene expression (Mantovani et al., 2004; Mantovani et al., 
2007; Zacchi et al., 2002; Zheng et al., 2002). 
Pin1 is involved also in the oxidative stress response by regulating mitochondrial 
import of p66Shc. This protein translates oxidative damage into cell death by 
producing reactive oxygen species within mitochondria, and is involved in regulation 
of lifespan (Migliaccio et al., 1999). Activation of PKCβ by oxidative conditions 
triggers phosphorylation of p66Shc and its mitochondrial accumulation after its 
recognition by Pin1 (Pinton et al., 2007), thus suggesting a role for Pin1 in oxidative 
stress and ageing. 
Recently, Pin1 was reported to promote the stability and the transcriptional activity of 
Oct4, thereby implying that this prolyl isomerase is indispensable for the self-renewal 
and maintenance of pluripotent stem cells (Nishi et al., 2011). 
 
 
Role of Pin1 in cancer 
 
A connection between Pin1 and cancer was first suggested when Pin1 was observed 
to be overexpressed in human cancer tissues (Ryo et al., 2001; Wulf et al., 2001). 
More extensive studies revealed that (with very few exceptions, such as neurons) in 
normal tissues Pin1 expression is associated with cell proliferation, and that it is 
overexpressed prevalently in human tumours, including breast, prostate, lung and 
colon cancers (Bao et al., 2004). Furthermore, increased Pin1 levels are highly 
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predictive of prostate cancer recurrence after prostatectomy (Ayala et al., 2003). 
Analysis of tumour molecular markers revealed a close correlation between Pin1 and 
cyclin D1 (Wulf et al., 2001). Because cyclin D1 is an important cell cycle regulator 
known to have a key role in the development of many cancers, this connection led to a 
series of in vitro and in vivo studies that demonstrated an essential role of Pin1 in 
regulating cyclin D1 expression and turnover through multiple mechanisms (figure 
12). 
 
 
Figure 12. Pin1 promotes oncogenesis by regulating multiple oncogenic signalling pathways at various 
levels. (Lu and Zhou, 2007) 
 
Phosphorylation of cyclin D1 by GSK-3β on the Thr 286-Pro motif promotes its 
nuclear export and subsequent ubiquitin-mediated degradation. However, Pin1 can 
directly bind to and isomerise this motif on cyclin D1, thereby preventing its nuclear 
export and degradation and resulting in cyclin D1 stabilization (Liou et al., 2002). 
Furthermore, Pin1 can also regulate cyclin D1 gene expression by at least three 
different mechanisms. First, in response to growth stimulating conditions, Pin1 can 
bind to the pSer 63/73-Pro motifs in c-Jun and multiple pS/T-P motifs in c-Fos, thus 
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increasing AP1 transcriptional activity towards its target genes such as cyclin D1 
(Wulf et al., 2001). 
Second, Pin1 can isomerase the pThr 246-Pro motif in β-catenin, preventing in this 
way its interaction with the tumour suppressor APC. This enhances transcriptional 
activity of β-catenin, as do many genetic mutations in β-catenin or APC that are 
found in human cancers (Ryo et al., 2001). Consistently, Pin1 overexpression and β-
catenin gene mutations have been shown to be distinct oncogenic events in human 
hepatocellular carcinoma (Pang et al., 2004). 
Third, after cytokine treatment, Pin1 can target to the pThr 254-Pro motif in the 
p65/RelA subunit of NF-κB and inhibit its binding to its negative regulator IκB. This 
prevents p65/RelA nuclear export and its subsequent degradation by a ubiquitin-
mediated pathway and promotes NF-κB transcriptional activity (Ryo et al., 2003). 
In addition, Pin1 can cooperate in promoting tumourigeneis since it is 
transcriptionally regulated by the E2F family of transcription factors in response to 
growth factors and other stimulating conditions such as activation of Her2/Neu or Ras 
(Ryo et al., 2002). This realizes a positive feedback loop, in which Her2/Neu or Ras 
activation leads to an increase in Pin1 levels through E2F-mediated transcription, and 
Pin1 in turn positively regulates cyclin D1 both at the transcriptional and post-
translational levels. Accordingly, Pin1 ablation was demonstrated to be highly 
effective in preventing oncogenic Her2/Neu or Ras from inducing cyclin D1 and 
breast cancer in mice (Wulf et al., 2004). 
Moreover, Pin1 also inhibits a negative feedback loop of MAPK signalling. In 
response to growth stimulating conditions, Raf kinase is activated by Ras and then 
triggers a protein kinase cascade, leading to the activation of MAPKs. MAPKs can 
phosphorylate and inactivate Raf in a negative feedback mechanism. Pin1 prevents 
Raf kinase from being turned off by promoting its dephosphorylation, thus 
maintaining activated the MAPK signalling (Dougherty et al., 2005). 
We have recently demonstrated that Pin1 can promote mammary tumourigenesis by 
interacting with Notch1 and allowing efficient Notch1 activation through the cleavage 
mediated by γ-secretase (Rustighi et al., 2009). In this way, Pin1 can promote Notch1 
transcriptional function and oncogenic activity, both in vitro and in vivo. Moreover, 
we have found that Notch1 is able to directly induce the transcription of Pin1, thereby 
generating a positive feedback loop through which Pin1 can enhance Notch1 
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signalling. In agreement with this, we have observed in human breast cancers a strong 
correlation between Pin1 overexpression and high levels of activated Notch1 
(Rustighi et al., 2009), see appendix. 
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4. AIM OF THE THESIS 
 
About half of all human cancers harbour mutations in the TP53 gene. Besides losing 
tumour suppressor functions, these mutant p53 proteins exert oncogenic activities 
(such as induction of migration and invasion, genomic instability and resistance to 
apoptosis), thus promoting tumour formation and progression. 
Evidence from in vivo studies highlighted that efficient gain of function is associated 
with elevated mutant p53 protein levels in tumour cells and tissues (Soussi and 
Beroud, 2001; Terzian et al., 2008), supporting the notion that stress signalling, 
generated by chronic DNA damage and activation of oncogenic pathways, could 
stabilize and activate mutant p53 within tumour cells, with mechanisms similar to 
those required to stimulate wild-type p53 (Song et al., 2007; Terzian et al., 2008). 
The work presented in this thesis aimed to investigate this hypothesis and to dissect 
the mechanisms underlying mutant p53 gain of function, focusing on factors that 
might link cancer-related signalling with mutant p53 activity. An intriguing candidate 
for this role is the phosphorylation-dependent prolyl isomerase Pin1, which 
transduces phosphorylation signalling into conformational changes affecting the 
functions of its substrates (Lu and Zhou, 2007; Yeh and Means, 2007). Other 
laboratories and ours have previously identified this enzyme as a critical regulator of 
wild-type p53 activities in cells exposed to genotoxic stress (Mantovani et al., 2007; 
Zacchi et al., 2002; Zheng et al., 2002). Although supporting wild-type p53 functions, 
Pin1 is frequently overexpressed in human tumours (Bao et al., 2004) and promotes 
both Her2/Neu/Ras and Notch1 dependent transformation (Rustighi et al., 2009; Wulf 
et al., 2004). 
Since several aspects of the regulation of wild-type and mutant p53 proteins are 
similar (Terzian et al., 2008), we reasoned that the physiological role of Pin1 as a 
component of checkpoint mechanisms might be subverted during tumourigenesis, 
thus becoming a crucial amplifier of mutant p53 oncogenic functions. 
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5. RESULTS 
 
5.1 Pin1 enhances tumourigenesis in a mutant p53 knockin mouse 
model 
 
To understand the impact of Pin1 on mutant p53 in tumorigenesis, we crossed mutant 
p53 knockin mice, bearing one knockin allele for p53R172H (p53M/+) and thereby 
representing a Li-Fraumeni mouse model (Lang et al., 2004), with Pin1+/- mice 
(Atchison et al., 2003). Two cohorts of compound mice, having either one or two 
knockin alleles with wild-type or knock-out Pin1 genotypes (p53M/+Pin1+/+, 
p53M/+Pin1-/- and p53M/MPin1+/+, p53M/MPin1-/-), were generated and monitored. 
Survival data for p53M/MPin1+/+ and p53M/+Pin1+/+ mice were consistent with 
published results (Lang et al., 2004). Mice lacking Pin1 displayed an increased 
median tumour-free survival in both cohorts (figure 13). 
 
 
Figure 13. Pin1 is required for mutant p53 dependent spontaneous tumourigenesis. Left panel: 
Tumour-free Kaplan-Meier survival curves of p53M/MPin1+/+ (n=27) and p53M/MPin1-/- (n=22) mice 
cohorts (X2 = 4, P = 0.02, Long-rank Mantel-Haenszel test). Right panel: Tumour-free Kaplan-Meier 
survival curves of p53M/+Pin1+/+ (n=19) and p53M/+Pin1-/- (n=17) mice cohorts (X2 = 5.4, P = 0.045, 
Long-rank Mantel-Haenszel test). p53+/+Pin1+/+ (n=22), p53+/+Pin1-/- (n=18). 
 
While in the p53M/M cohort absence of Pin1 caused variations only in the frequency of 
some tumour types, in the p53M/+Pin1-/- cohort, as compared to p53M/+Pin1+/+ mice, 
we observed a markedly reduced tumour frequency, a reduced number of lymphomas 
and notably a complete absence of carcinomas (figure 14). 
We also analyzed cohorts of p53+/-Pin1+/+ and p53+/-Pin1-/- mice and failed to observe 
any difference in tumour-free survival, tumour frequency or spectrum (data not 
shown). Therefore absence of Pin1 reduces spontaneous tumourigenesis exclusively 
in mice expressing mutant p53, suggesting their cooperation in tumour formation. 
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Figure 14. Pin1 affects tumour frequency and spectrum in a Li-Fraumeni mouse model. Left 
panel: Bar graph showing the proportion of mice of the indicated genotypes developing tumours. Right 
panel: Pie graphs representing the proportion of tumour types in p53M/+Pin1+/+ and p53M/+Pin1-/- mice 
relative to tumour totals. 
 
The genetic interaction between Pin1 and mutant p53 revealed above, prompted us to 
dissect the underlying mechanisms. First of all, we wanted to establish whether these 
two proteins interact in vivo and, as shown in figure 15, we could demonstrate that 
Pin1 coimmunoprecipitated with p53 in tumour samples from p53M/+Pin1+/+ mice. 
 
 
Figure 15. Pin1 and p53 interact in tumours. Upper panel: CoIP assay showing the interaction 
between endogenous Pin1 and p53 in tumours from p53M/+Pin1+/+ mice. T1: multicentric lymphoma, 
T2: mesenteric lymphoma. NRA: not related antibody. Lower panel: Western blot analysis of inputs. 
 
Given that Pin1 specifically recognizes phosphorylated S/T-P motifs on its substrates, 
our observation suggests that in tumour cells Pin1 might bind mutant p53 in response 
to oncogenic signalling-mediated phosphorylation to regulate its function. Therefore, 
we analyzed the effect of Pin1 on the ability of mutant p53 to enhance Ras-induced 
transformation of primary cells (Lang et al., 2004). Mouse embryo fibroblasts (MEFs) 
obtained from p53M/MPin1+/+, p53M/MPin1-/-, p53-/-Pin1+/+ or p53-/-Pin1-/- were tested 
for anchorage-independent growth as well as for their tumourigenic potential in vivo 
upon retroviral transduction of H-RasV12. Notably, p53M/MPin1+/+ cells formed two-
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fold more colonies in soft agar as compared with either p53M/MPin1-/- or p53-/- cells 
and, when injected subcutaneously into immuno-compromised mice, they developed 
tumours double in size (figure 16). 
 
 
Figure 16. Pin1 is necessary for the cooperation between Ras and mutant p53 in cell 
transformation. Left panel: Histogram of anchorage-independent growth of H-RasV12 transduced 
MEFs. Error bars indicate s.d. (n = 3), P relative to p53M/MPin1+/+ MEFs < 0.01 in all cases (two-tailed 
t-test). Middle panel: Bar graph representing volume of tumours originated by the indicated H-RasV12 
transduced MEFs injected in SCID NOD mice measured upon sacrifice. The graph shows the average 
volume and s.d. of tumours from 5 mice injected for each cell type. P relative to p53M/MPin1+/+ MEFs 
< 0.01 (two-tailed t-test). Right panel: Western blot analysis of mutant p53 and Pin1 protein levels in 
MEFs infected with H-RasV12 (+) or empty vector (-). 
 
In H-RasV12 transduced p53M/MPin1+/+ MEFs, coimmunoprecipitation (CoIP) 
experiments allowed us to confirm the interaction between the prolyl isomerase Pin1 
and mutant p53 (figure 17). 
 
Figure 17. Pin1 and mutant p53 interact in vivo. Western blot analysis of CoIP of endogenous Pin1 
and p53R172H in H-RasV12-transduced p53M/MPin1+/+ MEFs. NRA: not related antibody. 
 
In these cells, overexpression of H-RasV12 caused up-regulation of mutant p53 and 
Pin1 (see above figure 16), in agreement with previous observations (Ryo et al., 
2002). Importantly, immunoblotting with a phospho-S/T-P specific antibody showed 
that H-RasV12 overexpression increased phosphorylation of mutant p53 on putative 
Pin1 binding motifs and, as a consequence, the in vitro interaction between mutant 
p53 and Pin1 was enhanced (figure 18). All together these observations suggest that 
Pin1 is necessary for the ability of mutant p53 to promote both cell transformation 
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and tumorigenicity and reveal a role for Pin1 as a key transducer of oncogenic 
signalling towards activation of mutant p53 gain of function. 
 
Figure 18. Activated Ras promotes mutant p53 phosphorylation and binding to Pin1. Left panel: 
Western blot analysis of phosphorylated S-P or T-P sites (MPM-2 antibody) of normalized levels of 
immunoprecipitated p53R172H from p53M/MPin1+/+ MEFs infected with H-RasV12 (+) or empty vector 
(-). NRA: not related antibody. Right panel: Western blot analysis of GST-Pin1 pull-down assays using 
cell lysates as above. 
 
 
5.2 Pin1 potentiates mutant p53-dependent cell migration and 
invasion 
 
To establish whether Pin1 could sustain mutant p53 oncogenic function also in human 
cancer cells, we tested the ability of Pin1 to bind to endogenous mutant p53 in two 
human breast cancer cell lines MDA-MB-231 and SK-BR-3. In these cells, mutant 
p53 appeared to be constitutively phosphorylated on some putative Pin1 binding sites 
(S33 and S46), and to interact with Pin1 both in vitro and in vivo (figure 19). 
 
 
Figure 19. Mutant p53 is constitutively phosphorylated in human cancer cells and interacts with 
Pin1. (A) Endogenous mutant p53 was immunoprecipitated with DO1 antibody and phosphorylation 
on S33 and S46 was analyzed by western blot with phospho-specific antibodies recognizing p53 
modified on each site. Where indicated, cells were treated with doxorubicin for 18 h before lysis. (B) 
GST pull-down assays using recombinant GST-Pin1 and lysates from indicated human cell lines 
expressing endogenous mutant p53. Cells were treated as in (A). (C) CoIP assay showing interaction 
between endogenous Pin1 and mutant p53 in MDA-MB-231 cells. Upon lysis, mutant p53 or Pin1 
were immunoprecipitated with specific antibodies, as indicated, and as a negative control anti-GFP 
antibody was used. The presence of co-immunoprecipitated proteins was analyzed by western blot. 
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Furthermore, the interaction between Pin1 and mutant p53 was enhanced by H-RasV12 
overexpression (figure 20), in agreement with our results obtained in MEFs (see 
above figure 18). 
 
 
Figure 20. H-RasV12 overexpression promotes Pin1/mutant p53 interaction. Left panel: CoIP assay 
showing the interaction between endogenous Pin1 and mutant p53K280 ectopically expressed in 
H1299 cells (p53 null) along with pLPC-H-RasV12 or empty vector (-) as control. EGFP was co-
transfected as a control of transfection efficiency. Upon lysis, mutant p53 was immunoprecipitated 
with FL393 antibody. The presence of co-immunoprecipitated proteins was analyzed by western blot. 
Right panel: Western blot analysis of inputs. 
 
Since induction of migration and invasion are critical aspects of mutant p53 
dependent metastatic phenotype (Adorno et al., 2009; Muller et al., 2009), we 
evaluated whether Pin1 could play a role in these processes. RNAi-mediated 
knockdown of either mutant p53 or Pin1 significantly reduced both cell migration and 
invasion of MDA-MB-231 cells in transwell assays (figure 21). 
 
 
Figure 21. Pin1 and mutant p53 affect both cell migration and invasion. Transwell migration 
assays (A) and chemo-invasion assays (B) of MDA-MB-231 cells transfected with the indicated 
siRNAs (RNAi). Error bars indicate s.d. (n = 3). The effect on migration of two different Pin1 siRNA 
sequences (Pin1 (A) and Pin1 (B)) was analyzed. Lower panels show Pin1 and mutant p53 depletion 
analyzed through western blot. 
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The effect of Pin1 on cell migration was specific and required its enzymatic activity, 
since re-introduction of an siRNA-resistant Pin1 construct (Pin1r), but not a 
catalytically inactive Pin1 mutant (Pin1r S67E), restored migration (figure 22). 
 
 
Figure 22. Pin1 catalytic activity is required for cell migration. Transwell migration assays (left 
panel) and western blot (right panel) of MDA-MB-231 cells transfected with control (C) or Pin1 (A) 
siRNA upon transduction with retroviral vectors expressing siRNA resistant HA-Pin1r, HA-Pin1r 
S67E (catalytically inactive) or empty vector (-). Error bars indicate s.d. (n = 3). 
 
The impact of Pin1 on promoting invasion and metastasis was further evaluated in 
vivo, by injecting control- or Pin1-depleted MDA-MB-231 cells intravenously into 
immuno-compromised mice. The ability of Pin1 depleted cells to colonize the lungs 
was drastically reduced (figure 23). 
 
Figure 23. Pin1 depletion reduces lung colonization. Upper panels: Haematoxylin and eosin staining 
of representative sections of entire pulmonary lobes from mice inoculated with shLacZ-infected 
(control) or shPin1-infected cells (6 mice per each group), arrows indicate representative metastases. 
Lower images: Immunohistochemical detection of Pin1 expression (magnification x12.5). Inserts show 
a detailed view of the area indicated by the arrows (magnification x200). 
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We next asked whether Pin1 exerts these effects epistatically by modulating mutant 
p53 functions. As shown in figure 24, Pin1 overexpression in MDA-MB-231 cells 
causes a significant increase in cell migration and invasion, however simultaneous 
depletion of mutant p53 almost completely abolished these effects. 
 
 
Figure 24. Pin1 promotes cell migration and invasion acting through mutant p53. Transwell 
migration (A) and chemo-invasion (B) assays of MDA-MB-231 cells transfected with p53 or control 
siRNA upon transduction with pMSCV (-) or pMSCV HA-Pin1 retroviral vectors. Error bars indicate 
s.d. (n = 3). (C) Representative western blot analysis of cell lysates. 
 
In order to test whether direct interaction between Pin1 and mutant p53 is necessary 
for these phenotypes, we generated a modified form of the endogenous mutant p53 
(p53K280) that is unable to bind to Pin1 (p53K280-4M). In this construct alanine 
replaced serine or threonine residues in the four S/T-P phosphorylation and Pin1 
binding sites (S33, S46, T81 and S315) (Mantovani et al., 2007) (figure 25 A). We 
then compared the effect of p53K280 and p53K280-4M on migration of MDA-MB-
231 cells in which endogenous mutant p53 was selectively depleted using an siRNA 
targeting the 3’UTR of its mRNA (p53u). Re-introduction of an siRNA-resistant 
p53K280 resulted in complete rescue of migration, while almost no effect was 
observed in cells expressing p53K280-4M. Notably, upon Pin1 overexpression we 
observed an increased migration in p53K280 but not in p53K280-4M expressing cells 
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(figure 25 B). 
 
Figure 25. Pin1/mutant p53 interaction is required for induction of cell migration. (A) Upper 
panel: Schematic representation of the domain organization of p53 in which the four mutated S/T-P 
sites and the R280K mutation are indicated. Lower panel: GST pull-down assay with recombinant 
GST-Pin1 performed using lysates from H1299 cells transfected with plasmids expressing p53K280 or 
p53K280-4M, where S33, S46, T81 and S315 were changed to alanines. (B) Transwell migration 
assays (left panel) and western blot analysis (right panel) of MDA-MB-231 cells co-transduced with 
pMSCV or pMSCV HA-Pin1 along with empty vector (-), HA-p53K280 or HA-p53K280-4M 
retroviral constructs. Specific depletion of endogenous mutant p53 was achieved transfecting an siRNA 
targeting the 3’UTR (p53u). Error bars indicate s.d. (n = 3, *: P < 0.001, two-tailed t-test). (C) 
Transwell migration assays (left panel) and western blot analysis (right panel) of MDA-MB-231 cells 
co-transduced with pMSCV or pMSCV HA-Pin1 along with retroviral constructs expressing the 
indicated mutant p53 constructs or empty vector (-). Endogenous mutant p53 was knocked down as in 
(B). Error bars indicate s.d. (n = 3). *: P value relative to HA-p53K280-4M (two-tailed t-test). pMSCV 
transduced cells: P < 0.001 for p53K280, P < 0.01 for p53K280-3MS46, P < 0.05 for p53K280-
3MS315. pMSCV HA-Pin1 transduced cells: P < 0.001 for p53K280 and p53K280-3MS46, P < 0.05 
for p53K280-3MS315. 
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To evaluate which of the four phosphorylation sites in mutant p53 were important to 
promote this phenotype, wild-type amino acids were separately re-introduced into 
p53K280-4M on each of the alanine substitutions and the resulting four different 
p53K280-3M constructs were tested for the ability to rescue cell migration upon 
depletion of endogenous mutant p53. Only constructs containing wild-type S46 or 
S315 allowed recovery of cell migration and their effect was even more evident when 
Pin1 was overexpressed (figure 25 C). 
Overall, these results strongly suggest that phosphorylation of S/T-P sites in mutant 
p53 promotes Pin1 binding to unleash mutant p53 pro-migration activities. 
 
 
5.3 Pin1 impacts mutant p53 transcriptional regulation 
 
Mutant p53 was reported to enhance cell migration and invasion by sequestering and 
inactivating the anti-metastatic factor p63 (Adorno et al., 2009; Muller et al., 2009). 
Therefore, we asked whether Pin1 could affect these phenotypes by promoting the 
mutant p53-p63 interaction. CoIP assays performed in MDA-MB-231 cells showed 
that Pin1 overexpression increased the association between endogenous p63 and 
mutant p53 (figure 26 A). In contrast, when we compared p53K280 with p53K280-
4M for p63 binding, we could observe that p53K280-4M did not efficiently associate 
with p63 (figure 26 B), indicating that phosphorylation on these sites and Pin1 
binding are required for interaction with p63. 
 
 
Figure 26. p63/mutant p53 complex is affected by mutant p53 phosphorylation and interaction 
with Pin1. (A) Co-IP of endogenous p63 and mutant p53 from MDA-MB-231 cells transduced with 
HA-Pin1 retroviral construct or empty vector. NRA: not related antibody. Protein inputs (5% of lysate) 
are shown. (B) Co-IP of endogenous p63 and ectopically expressed HA-p53K280 or HA-p53K280-4M 
in MDA-MB-231 cells by transducing the indicated retroviral constructs. As a negative control, empty 
vector (-) was used. Protein inputs (5% of lysate) are shown below. 
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Accordingly, upon Pin1 overexpression, the transcriptional function of p63 was 
curbed, as judged from reduced expression of Sharp-1 and CCNG2, two target genes 
involved in suppression of migration and invasion (Adorno et al., 2009) (figure 27 A). 
Overall, these results show that Pin1 contributes to mutant p53 activity by 
potentiating its ability to block p63 function. 
Notably, upon Pin1 overexpression we also observed a three-fold increase in mRNA 
levels of CCNA2, a known direct target gene of the mutant p53-NF-Y complex (Di 
Agostino et al., 2006) (figure 27 B). This suggests that Pin1, besides p63 inactivation, 
could influence other mutant p53 transcriptional functions. 
 
 
Figure 27. Pin1 inhibits p63 transcriptional activity and affects mutant p53 target genes. Effect of 
Pin1 overexpression on the expression of p63 targets CCNG2 and Sharp-1 (A) or mutant p53 target 
CCNA2 (B). mRNA levels were determined by qRT-PCR in MDA-MB-231 cells upon transduction 
with empty vector (-) or HA-Pin1 retroviral construct. Error bars indicate s.d. (n = 3). 
 
 
5.4 A Pin1/mutant p53 axis activates a pro-aggressiveness 
transcriptional program 
 
To investigate how Pin1 and mutant p53 may globally alter gene expression, we 
analyzed the transcription profiles of MDA-MB-231 cells upon depletion of either 
Pin1 or mutant p53. Unbiased analysis of functional annotation (AFA) showed that 
the same categories of genes were affected under both conditions, implying that Pin1 
and mutant p53 are involved in the regulation of similar cellular processes, including 
proliferation, motility, cytoskeleton dynamics, metabolism and signal transduction 
(data not shown). In particular, we identified 386 genes that were up-regulated and 
303 genes that were down-regulated by either depletion of Pin1 or mutant p53, 
suggesting that a group of genes may be regulated by the concerted action of these 
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two proteins (figure 28 A). The effect of Pin1 and mutant p53 depletion on the 
expression of selected genes was confirmed by qRT-PCR (figure 28 B). 
 
Figure 28. Pin1 and mutant p53 regulates common target genes. (A) Venn diagram showing the 
overlap between genes perturbed by depletion of either Pin1 (siPin1) or mutant p53 (sip53) in MDA-
MB-231 cells, red: up-regulated genes, green: down-regulated genes. (B) qRT-PCR validation of 
selected genes. Changes in gene expression are indicated as fold change upon Pin1 (siPin1) or mutant 
p53 (sip53) depletion in MDA-MB-231 cells relative to cells transfected with control siRNA. Error 
bars indicate s.d. (n = 3). 
 
We hypothesized that if the transcriptional program induced by mutant p53 and Pin1 
contained genes relevant for tumour aggressiveness, it could influence breast cancer 
prognosis. To test this idea, we analyzed primary tumours for correlations between 
the expression of genes induced by Pin1 and mutant p53 (i.e. genes down-regulated in 
our profiling experiments) and disease prognosis, using four independent datasets of 
breast cancer (Desmedt et al., 2007; Miller et al., 2005; Pawitan et al., 2005; Sotiriou 
et al., 2006), which collectively consist of more than 800 patients. Among the 303 
down-regulated genes, we selected the top repressed ones in both conditions of 
silencing. The Desmedt dataset (Desmedt et al., 2007) was used as a training set to 
build a gene rank based on clinical data correlation and we selected the ten top 
scoring genes to define a Pin1/mutant p53 signature (table 1). 
 
Table 1. Pin1/mutant p53 10 genes signature. 
 
ENTREZ ID Symbol Gene name 
699 BUB1 budding uninhibited by benzimidazoles 1 
54069 C21orf45 chromosome 21 open reading frame 45 
9134 CCNE2 cyclin E2 
1058 CENPA centromere protein A 
11052 CPSF6 cleavage and polyadenylation specific factor 6 
55635 DEPDC1 DEP domain containing 1 
54566 EPB41L4B erythrocyte membrane protein band 4.1 like 4B 
54478 FAM64A family with sequence similarity 64, member A 
23397 NCAPH non-SMC condensin I complex, subunit H 
93594 WDR67 WD repeat domain 67 
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Kaplan-Meier survival analysis showed that expression of these genes significantly 
correlated with clinical outcome: patients expressing high levels displayed a shorter 
time to distant metastasis (TDM) and a reduced overall survival (figure 29 and data 
not shown). 
 
 
Figure 29. Pin1/mutant p53 signature correlates with clinical outcome in breast cancer. Kaplan-
Meier survival curves of time to distant metastasis (TDM) of breast cancer patients classified according 
to the expression of the Pin1/mutant p53 signature. Red line: cases with high expression of the 10 
genes, blue line: cases with low expression of the 10 genes. (A): Desmedt dataset (Desmedt et al., 
2007) (X2 = 25.6, P = 4.1 x 10-7, n = 198, Log-Rank Test). (B): Sotiriou dataset (Sotiriou et al., 2006) 
(X2 = 7.2, P = 0.0074, n = 179, Log-Rank Test). 
 
 
We next investigated whether these ten genes are regulated by the concerted action of 
Pin1 and mutant p53. As shown in figure 30 A, in MDA-MB-231 cells depleted of 
endogenous mutant p53, re-introduction of p53K280, but not of p53K280-4M, 
induced the expression of all these genes. More importantly, ectopic expression of 
Pin1 together with p53K280 strongly enhanced their transcription. On the contrary, 
when Pin1 was overexpressed alone or together with p53K280-4M, the expression of 
these genes was not affected (figure 30 A). To dissect the mechanisms by which the 
concerted action of Pin1 and mutant p53 enhances transcription, we performed 
chromatin immunoprecipitation experiments (ChIP) in MDA-MB-231 cells. As 
shown in figure 30 B, mutant p53 is specifically recruited on the promoters of all the 
Pin1/mutant p53 signature genes, while upon Pin1 depletion its recruitment was 
reduced by approximately two fold. On the other hand, also Pin1 is present on these 
promoters, but only in a mutant p53 dependent manner (figure 30 C). 
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Figure 30. Concerted action of Pin1 and mutant p53 is required for the expression of the 10 
genes. (A) Bar graph showing fold change in expression of the Pin1/mutant p53 signature genes or an 
unaffected control gene (PARP3) analyzed by qRT-PCR in MDA-MB-231 cells upon co-transduction 
of pMSCV or pMSCV HA-Pin1 with the indicated p53 mutants or empty vector (-) as a negative 
control. Endogenous mutant p53 was depleted as in figure 25 B and C. (n = 3, *: P < 0.001 comparing 
the expression of each gene from the Pin1/mutant p53 signature between the indicated conditions, two-
tailed t-test). (B) ChIP analysis of mutant p53-bound chromatin (IP p53) from MDA-MB-231 cells 
upon transduction with shRNA vectors targeting endogenous Pin1 (shPin1), mutant p53 (shp53) or 
LacZ as a negative control (shLacZ). Chromatin was immunoprecipitated with DO1 antibody or mouse 
purified IgGs as negative control (NRA). Promoter occupancy was analyzed by qRT-PCR and 
calculated as percentage of input chromatin. (n = 3, *: P < 0.013 comparing promoter occupancy for 
each gene from the Pin1/mutant p53 signature between the indicated conditions, not including the 
negative control, two-tailed t-test). (C) ChIP analysis of Pin1-bound chromatin (IP Pin1) from MDA-
MB-231 cells upon transduction with shRNA vectors targeting endogenous Pin1 (shPin1), mutant p53 
(shp53) or lacZ as a negative control (shLacZ). Chromatin was immunoprecipitated with Pin1 
polyclonal antibody or rabbit purified IgGs as negative control (NRA). Promoter occupancy was 
analyzed as in (B). (B) and (C) control (white box) indicates a DEPDC1 promoter region not bound by 
mutant p53 nor Pin1. (A)-(C) Error bars indicate s.d. (n=3, two-tailed t-test). 
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Altogether our data suggest that these genes are direct targets for transcriptional 
induction by the Pin1/mutant p53 axis and that Pin1 could be required for the proper 
interaction of mutant p53 with functional sites on chromatin. In this respect, 
inspection of these promoter regions revealed the presence of consensus binding sites 
for transcription factors known to interact with mutant p53, such as Ets-1, NF-Y, Sp1 
and VDR (Brosh and Rotter, 2009) (data not shown). 
The majority of these genes appeared to be regulated by Pin1 and mutant p53 also in 
MDA-MB-468 cells that express endogenous p53H273 (figure 31), indicating that 
Pin1 could also affect the transcriptional activity of other p53 mutants. 
 
Figure 31. Pin1 and mutant p53 regulate the 10 signature genes also in MDA-MB-468 cells. 
mRNA levels were determined by qRT-PCR upon transfection of the indicated siRNAs. Changes in 
gene expression are indicated as fold change upon Pin1 or mutant p53 depletion relative to cells 
transfected with control siRNA. Error bars indicate s.d. (n = 3. *: P value < 0.028 comparing the 
expression of each gene from the Pin1/mutant p53 signature in cells transfected with the indicated 
siRNAs versus control, two-tailed t-test). 
 
To investigate the functional roles of these ten genes as mediators of Pin1/mutant 
p53-dependent cell migration, we analyzed the effect of their silencing in MDA-MB-
231 cells. We identified six genes that, when depleted, reduced migration without 
affecting cell viability (figure 32). 
 
Figure 32. Pin1/mutant p53 target genes affect cell migration. (A) Wound healing-based siRNA 
analysis. Left panel: bar graph showing the percentage of well surface covered by migrating cells 24 h 
upon silencing of the indicated genes (n = 4, ***: P < 0.001 relative to LacZ siRNA, two-tailed t-test). 
Right panel: representative images of the assay. (B) Graph representing the effect of indicated siRNAs 
on cell viability versus cell migration in MDA-MB-231 cells. Percentage of cell viability is referred to 
control siRNA (LacZ) transfected cells. 
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Interestingly in this assay the strongest effect was shown by DEPDC1, which was 
reported to be involved in proliferation of bladder cancer cells and to be 
overexpressed in breast cancer (Kanehira et al., 2007; Kretschmer et al., 2011; 
Sparano et al., 2009). Depletion of this gene in MDA-MB-231 cells had an impact 
also on invasiveness (figure 33). 
 
Figure 33. Depletion of Depdc1 reduces cell invasion. Left panel: DEPDC1 knockdown upon 
transfection with two different siRNAs (DEPDC1 (A) and DEPDC1 (B)) was analyzed by qRT-PCR in 
MDA-MB-231 cells. Right panel: chemo-invasion assays of MDA-MB-231 cells upon DEPDC1 
depletion. Error bars indicate s.d. (n = 3). 
 
Accordingly, when ovexpressed in MDA-MB-231 cells, DEPDC1 enhanced cell 
migration and, notably, was able to rescue the phenotype caused by mutant p53 
depletion (figure 34). 
 
Figure 34. Depdc1 promotes cell migration acting downstream of mutant p53. Left panel: 
Transwell migration assays performed in MDA-MB-231 cells transfected with vectors expressing two 
DEPDC1 isoforms (DEPDC1-1 and DEPDC1-2) upon control (C) or mutant p53 depletion. As a 
negative control empty vector was used (-). Error bars indicate s.d. (n = 3). Right panel: Western blot 
analysis of cell lysates. 
 
 
Collectively, these results show that Pin1 acts in concert with mutant p53 to 
reprogram gene expression in tumour cells, activating a transcriptional program which 
includes a previously unknown set of mutant p53 direct target genes relevant for 
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migration and invasion. 
 
 
5.5 Pin1 levels and p53 mutation modulate clinical outcome in breast 
cancer 
 
We next investigated the association of Pin1 expression and p53 mutation status with 
clinical outcome in breast cancer. Quantitative immunohistochemistry (IHC) was 
used to analyze Pin1 and p53 protein expression in primary breast carcinomas. The 
status of p53 was analyzed by direct sequencing, and only tumours bearing either 
wild-type p53 or p53 missense mutations where included in this study, resulting in a 
series of 212 cases. Pin1 was overexpressed in 144/212 (68%) cases while missense 
mutations in TP53 were detected in 46/212 (22%) cases (table 2). 
 
Table 2. Pin1 levels and p53 status in the analyzed cohort. 
 
 Wild-type p53 Mutant p53 Total 
High Pin1 111 32 143 
Low Pin1 55 14 69 
Total 166 46 212 
 
Overall survival (OS) was not associated with Pin1 overexpression (figure 35 A). 
However, consistent with previous observations (Langerød et al., 2007; Olivier et al., 
2006), OS was decreased in cases with p53 missense mutations (figure 35 B). 
 
 
Figure 35. Association between overall survival and either Pin1 levels or p53 mutation. (A) 
Kaplan-Meier analysis of 10 years OS in cases that overexpress Pin1 (red line) or do not overexpress 
Pin1 (blue line). (X2 = 0.015, P = 0.903, n = 212, Log-Rank test). (B) Kaplan-Meier analysis of 10 
years OS in cases with p53 mutation (red line) or with wild-type p53 (blue line) (X2 = 21.43, P < 0.001, 
n = 212, Log-Rank test). 
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Remarkably, when we determined OS as a function of the combination between Pin1 
expression and presence of p53 missense mutations, we found that it was significantly 
decreased in patients with tumours expressing high levels of Pin1 (high Pin1) and 
mutant p53, compared to low Pin1 expression (low Pin1) and mutant p53, or wild-
type p53 cases (figure 36 A). Moreover, multivariate Cox proportional-hazards 
analysis showed that the combination of Pin1 overexpression and p53 mutation 
behaved as an independent predictor of clinical outcome (figure 36 B). 
 
 
Figure 36. Breast cancer patients with tumours bearing high Pin1 levels and mutant p53 have the 
poorest clinical outcome. (A) Kaplan-Meier survival curves of breast cancer patients (observation 
threshold 10 years, clinical variable = OS) as a function of the combination of Pin1 overexpression and 
presence of p53 missense mutations. Low Pin1: tumours not overexpressing Pin1, high Pin1: tumours 
overexpressing Pin1 (X2 = 17.2, P < 10-4, n = 212, Log-Rank test). (B) Multivariate analysis of risk of 
death. Multivariate analysis was performed on the same cohort of patients analyzed in (A) using Cox 
proportional-hazards regression modelling. The relationships between survival and high Pin1 levels 
and TP53 missense mutation or other clinical variables used in the clinical practice are shown. 
 
The dependence of the prognostic value of p53 mutation on Pin1 expression is further 
highlighted by the observation that p53 mutation correlates with shorter OS only in 
cases with high Pin1 expression levels (figure 37). 
Notably, Pin1 expression and p53 missense mutation were associated with poor 
outcome in patients treated with anthracycline-based adjuvant chemotherapy. Also in 
this subgroup the combination of Pin1 overexpression and p53 mutation behaved as 
an independent prognostic factor (figure 38). Taken together, these results 
demonstrate that Pin1 levels significantly affect the association between mutant p53 
and clinical outcome in breast cancer. 
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Figure 37. High Pin1 levels influence the prognostic value of p53 missense mutation in breast 
cancer. (A) Kaplan-Meier survival curves of breast cancer patients with high expression of Pin1 
(observation threshold 10 years, clinical variable = OS) as a function of the presence of p53 missense 
mutation or wild-type p53 (X2 = 14.1, P < 10-4, n = 143, Log-Rank test). (B) Kaplan-Meier survival 
curves of breast cancer patients with low expression of Pin1 (observation threshold 10 years, clinical 
variable = OS) as a function of the presence of p53 missense mutation or wild-type p53 (X2 = 0.4, P = 
0.548, n = 69, Log-Rank test). 
 
 
 
Figure 38. High Pin1 levels and p53 missense mutation correlate to poor response to 
anthracycline-based adjuvant chemotherapy. Multivariate Cox proportional-hazards analysis of risk 
of death on cases receiving anthracycline-based adjuvant chemotherapy as a function of Pin1 
overexpression and presence of p53 missense mutations (n = 66). 
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6. DISCUSSION 
 
Studies in mutant p53 knockin mice have underscored the requirement of an 
oncogenic context to activate mutant p53 function (Lang et al., 2004; Olive et al., 
2004; Terzian et al., 2008). With our findings, we provide a link between oncogenic 
signalling and the acquisition of aggressive phenotypes showing that, in tumour cells, 
the phosphorylation-dependent prolyl isomerase Pin1 and mutant p53 become 
integrated into a molecular axis, activated by phosphorylation of critical S/T-P sites 
on mutant p53. 
Our evidence that lack of Pin1 hampers tumourigenesis in mice expressing mutant 
p53, strongly suggests a critical role for this isomerase in transducing oncogenic 
signaling to elicit mutant p53 activity. This notion is further emphasized by our data 
obtained in p53M/M MEFs transduced with H-RasV12, where enhanced tumourigenicity 
was strictly dependent on Pin1. In these cells, oncogenic signalling caused increased 
Pin1 expression paralleled by mutant p53 phosphorylation on S/T-P sites, leading to 
their interaction. The in vivo cooperation between Ras and mutant p53 has been 
described in mouse models of malignant skin and pancreatic carcinomas (Caulin et 
al., 2007; Hingorani et al., 2005). Based on our results it is conceivable that also in 
those models Pin1 could be critical in linking oncogenic signalling with full activation 
of mutant p53, leading to increased genomic instability and metastasis. 
Our results revealed that in breast cancer cells aberrant signalling causes 
phosphorylation of mutant p53 on S/T-P sites, which promotes its recognition by 
Pin1, as a necessary step to unleash mutant p53 dependent migration and invasion. 
Recently mutant p53 has been shown to enhance the metastatic potential of human 
tumour cell lines (Adorno et al., 2009; Muller et al., 2009). In particular, in breast 
cancer cells, mutant p53 acts as a molecular switch for TGF-β triggered metastasis by 
curbing p63 transcriptional activity through the formation of a ternary complex with 
Smad proteins (Adorno et al., 2009). Our finding that Pin1 potentiates the p63-mutant 
p53 interaction, suggests that Pin1 could function downstream of TGF-β signalling, to 
contribute to down-regulation of two p63 anti-metastatic target genes. 
Our results indicate that the concerted action of Pin1 and mutant p53 promotes 
tumour aggressiveness also by inducing a specific transcriptional program. Among 
the Pin1/mutant p53 targets, we identified a 10-gene signature showing significant 
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correlation with clinical outcome in four independent breast cancer datasets. 
Interestingly, three of these genes, BUB1, CCNE2 and CENPA are present in a gene 
signature predictive of early metastasis in breast cancer (van 't Veer et al., 2002). In 
addition, C21orf45 was shown to sustain tumour cells’ addiction to oncogenic K-Ras 
(Luo et al., 2009), while CPSF6 was found both up-regulated by Snail in human colon 
cancer and fused to FGFR1 in haematological malignancies (Hidalgo-Curtis et al., 
2008; Larriba et al., 2010). 
These ten genes are bona fide direct target genes of the Pin1/mutant p53 axis and act 
as key effectors of mutant p53-dependent migration and invasion. None of these 
genes harbours wild-type p53 consensus binding sites on their promoters (data not 
shown). Instead, the promoter regions of these genes analyzed by ChIP contain 
consensus binding sites for transcription factors previously shown to tether mutant 
p53 on cognate promoters and to contribute to mutant p53 gain of function, such as 
Ets-1, NF-Y, Sp1 and VDR (Brosh and Rotter, 2009). The evidence that Pin1 
depletion hampers mutant p53 recruitment on chromatin suggests that Pin1 could be 
required for the proper interaction of mutant p53 with these transcriptional partners on 
specific gene promoters. 
Altogether our data imply that in cancer cells, the combined activities of Pin1 and 
mutant p53 have a profound impact on gene expression, both by inhibiting the activity 
of transcription factors, such as p63, thus dampening their tumour suppressor 
functions, and also by directly activating a transcriptional program that promotes 
tumour aggressiveness (figure 39). 
The clinical relevance of the Pin1/mutant p53 axis is further demonstrated by our 
results in a cohort of breast cancer patients. This analysis revealed that the prognostic 
value of p53 mutation was strongly improved by combining it with quantification of 
Pin1 levels. Studies including larger numbers of cases are required to validate this 
combination as a prognostic tool. Nevertheless, multivariate analysis showed that 
concomitant high Pin1 expression and p53 mutation behaved as an independent and 
strong predictor of clinical outcome. In tumours overexpressing Pin1, indeed, p53 
status allowed a better stratification of patients into groups of long or short term 
overall survival and this was also observed among patients who received 
anthracycline-based adjuvant chemotherapy. 
Our data suggest that patients bearing high Pin1 levels and mutant p53 could benefit 
from inhibition of the Pin1/mutant p53 axis. Proposed strategies based on inactivation 
Discussion 
 71 
of mutant p53 are represented by small molecules that reactivate wild-type like 
functions (Selivanova and Wiman, 2007), or peptides that kill cancer cells expressing 
mutant p53 (Di Agostino et al., 2008; Guida et al., 2008). By analyzing upstream and 
downstream molecular mechanisms that impinge on mutant p53 function, we 
identified additional potential targets for clinical intervention such as Pin1 or the 
kinases acting on mutant p53, as well as downstream effectors of the Pin1/mutant p53 
axis. 
Mutations in TP53 are frequent in basal-like breast cancer (Langerød et al., 2007), a 
subgroup of tumours consisting mostly of triple-negative cases, which have a higher 
risk of recurrence and whose management still represents a clinical challenge. Some 
of the Pin1/mutant p53 signature genes (e.g. BUB1, CENPA, DEPDC1), that we 
found modulated in two triple negative breast cancer cell lines, are also overexpressed 
in triple negative breast cancers (Sparano et al., 2009). Therefore our findings carry 
therapeutic implications for this kind of cancers and possibly also for other tumours 
bearing mutant p53 and high levels of Pin1. 
 
 
Figure 39. Working model. Schematic representation summarizing the main findings regarding the 
role of Pin1 and mutant p53 in the promotion of an aggressive tumour phenotype. 
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7. MATERIALS AND METHODS 
 
Mice strains and analysis. Mouse cohorts were generated by mating p53M/+ or p53+/- with Pin1+/- 
mice maintained on a C57BL/6 background and genotyping was performed by PCR analysis as 
described (Atchison et al., 2003; Lang et al., 2004). Animals showing signs of illness or evident tumour 
burden were sacrificed and organs were fixed in 10% formalin/PBS for 24 h. Tissues were embedded 
in paraffin, sectioned at 5 µm, dewaxed and stained with haematoxylin and eosin before pathological 
analysis. Procedures involving animals conformed to institutional guidelines that comply with 
international laws and policies (UKCCCR, 1989). 
 
Cell culture and constructs. MDA-MB-231 (p53R280K) and MDA-MB-468 (p53R273H) are triple-
negative breast cancer cells. SK-BR-3 (p53R175H) are HER2-overexpressing breast cancer cells. 
HaCaT (H179Y and R282W) are immortalized human keratinocytes. All these cell lines bearing 
endogenous mutant p53 do not express wild-type p53. U2OS, an osteosarcoma cell line, expresses 
wild-type p53, while H1299, a non-small cell lung cancer cell line, is p53 null. H1299 cells were 
maintained in culture in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 
10% foetal bovine serum (FBS), penicillin (100 IU/ml) and streptomycin (100 IU/ml). All the other cell 
lines were maintained in culture in Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 
10% FBS, penicillin (100 IU/ml) and streptomycin (100 IU/ml). MEFs were generated by crossing 
mice of the appropriate genotype and collecting cells from 13.5 d.p.c. embryos as described (Zacchi et 
al., 2002). pLPC-H-RasV12 was kindly provided by M. Serrano, pGEX-Pin1 was previously described 
(Zacchi et al., 2002). pcDNA3-p53K280 and pcDNA3-p53K280-4M were generated by site specific 
mutagenesis using pcDNA3-p53 and pcDNA3-4Mp53 as templates as previously described (Zacchi et 
al., 2002). 
pMSCV-HAPin1 was generated by subcloning Pin1 coding sequence from pcDNA3-HAPin1 
(Mantovani et al., 2007) in pMSCV vector. pMSCV-HAPin1r and pMSCV-HAPin1r S67E were 
generated introducing silent mutations in the region targeted by Pin1 siRNA (A) by site directed 
mutagenesis in pcDNA3-HAPin1 or pcDNA3-HAPin1 S67E (Rustighi et al., 2009) and then 
subcloning in pMSCV vector. pLPC-p53K280 and pLPC-p53K280-4M were generated by subcloning 
the respective coding regions in pLPC containing an HA tag. pLPC-p53K280-3M-S33, pLPC-
p53K280-3M-S46, pLPC-p53K280-3M-T81 and pLPC-p53K280-3M-S315 were generated by site 
specific mutagenesis using pLPC-p53K280-4M as a template. pSRshPin1 plasmid was generated by 
cloning Pin1 (A) double stranded siRNA (see below) in pSuper Retro vector. pSRshp53 plasmid was 
kindly provided by R. Agami. 
 
Transfection and retroviral transduction. For DNA transfection Lipofectamine 2000 (Invitrogen) 
was used and for siRNA transfection double-stranded RNA oligos (10 pmol/cm2) were transfected 
using Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s instructions. Retroviruses 
were made by transient transfection of 293 GP packaging cells with the appropriate plasmids in 
combination with pMD2-ENV coding for envelope proteins, using standard calcium-phosphate 
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method. After 48 h incubation at 32°C, the supernatants containing viral particles were collected and 
infection was performed as described (Zacchi et al., 2002). Infected cells were enriched by drug 
selection (Puromycin and Blasticidin, 2µg/ml each) for at least one week. 
 
siRNAs sequences used: 
 
siRNA Sequence (Sense, 5’-3’) Targeted gene Species 
DEPDC1 (A) UUCCGUAGUCUAAGAUAACUA DEPDC1 H. sapiens 
DEPDC1 (B) CAACAUGGCCAAUACAAGUAA DEPDC1 H. sapiens 
Pin1 (A) CGGGAGAGGAGGACUUUGA Pin1 H. sapiens 
Pin1 (B) GCCAUUUGAAGACGCCUCG Pin1 H. sapiens 
p53 GACUCCAGUGGUAAUCUAC TP53 H. sapiens 
p53u GGUGAACCUUAGUACCUAA TP53 H. sapiens 
Control (LacZ) GUGACCAGCGAAUACCUGU Beta-D-galactosidase E. coli 
 
Transformation assays and in vivo tumorigenicity. Low-passage MEFs infected with pLPC H-
RasV12 or empty vector were resuspended in DMEM supplemented with 10% FBS, penicillin (100 
IU/ml) and streptomycin (100 IU/ml), containing 0.3% agarose and plated on top of 1% agarose in the 
same medium, at a cell density of 1x105 for each 60-mm plate. After 14 days in culture, colonies 
reaching at least 100 µm were scored. Experiments were performed in triplicate using at least two 
different clones for each genotype. To assess tumourigenicity of H-RasV12 infected MEFs, 1x106 cells 
were injected subcutaneously on both sides in NOD SCID mice and after two weeks tumour volume 
was determined by calliper measurements, as described (Rustighi et al., 2009). 
 
Protein interaction studies and Western blot. GST pull-down assays were performed using 
recombinant GST-Pin1 or GST purified from bacteria as previously described (Zacchi et al., 2002). For 
CoIP of endogenous Pin1 and mutant p53 in MDA-MB-231 cells and for CoIP of endogenous Pin1 and 
ectopically expressed p53K280 in H1299 cells, cells were harvested and lysed in 50 mM Tris-HCl pH 
8.0, 100 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1 % Triton X-100, 10 % glycerol supplemented with 
phosphatase and protease inhibitors, and lysates were cleared by centrifugation. Protein G-sepharose 
bound antibodies were cross-linked using 5 mg/ml dimethylpimelimidate (Pierce), and incubated 
overnight with 0.5 mg/ml BSA. Lysates were pre-cleared with protein G-sepharose for 30 min before 
incubation for 2 h with cross-linked antibodies. Pin1 polyclonal (Rustighi et al., 2009) or p53 FL393 
(Santa Cruz) antibodies were used for IP in MDA-MB-231 cells and anti-GFP antibody (Santa Cruz) as 
negative control. p53 FL393 antibody was used for IP in H1299 cells. Beads were washed three times 
in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 % NP-40. Analysis of immunocomplexes 
was performed by western blot using Pin1 polyclonal antibody or p53DO1 (Santa Cruz). CoIP of p63 
and mutant p53 in MDA-MB-231 cells was performed as previously described (Adorno et al., 2009), 
anti-GFP antibody was used as negative control. 
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For CoIP of endogenous Pin1 and mutant p53 from mouse samples, Pin1 polyclonal or p53Pab421 
(Upstate) antibodies were used for IP, and rabbit purified IgGs as negative control. Analysis of Pin1 in 
immunocomplexes was performed by western blot using Pin1 polyclonal or monoclonal (Santa Cruz) 
antibodies. For mutant p53, 1C12 antibody (Cell Signalling) was used in western blots of 
immunoprecipitates from MEFs. 
Western blot analysis was performed as previously described (Zacchi et al., 2002). Antibodies against 
p53 (DO1), H-Ras (C20), p63 (4A4), p63 (H-137) and p63 (H-129) were purchased from Santa Cruz 
Biotechnology, p53 1C12, phospho-S33 p53 and phospho-S46 p53 from Cell Signaling, anti-actin and 
anti-HA from Sigma. For S/T-P phosphorylation analysis, p53 R172H from MEFs was immune-
precipitated with anti-p53 PAb421 and probed by western blot with MPM2 antibody (Upstate). 
 
Migration and invasion assays. For migration analysis, transfected cells (1x105) were plated on 24 
well PET inserts (8.0 µm pore size, Falcon), according to the manufacturer’s instructions. For invasion 
assays cells (1x105) were plated on matrigel-coated filters (8.0 µm pore size, Falcon) and the lower part 
of the chamber was filled with NIH3T3 conditioned DMEM 10% FBS medium as chemo-attractant. 
After 16 h or 24 h respectively, cells on the upper part of the membrane were removed with a cotton 
swab and cells that passed through the filter were fixed in 4% PFA, stained with 0.05% crystal violet 
and counted. 
 
In vivo metastasis assays and immunohistochemical staining. For lung colonization assays MDA-
MB-231cells were transduced with pSR shLacZ or pSR shPin1 (six animals per group). 106 cells were 
resuspended in 100 µl of PBS and inoculated in the tail vein of SCID mice. Upon sacrifice, lungs were 
fixed in 10% formalin/PBS for 24 h and embedded in paraffin. Sections were dried for 1 h at 57 °C, 
before being de-parafinized o.n. in Bioclear (Bioptica) and then rehydrated through a graded alcohol 
series. As antigen retrieval method, sections were steamed for 45 min in 10 mM Citric acid buffer, pH 
6.0. To quench the endogenous peroxidase activity, sections were incubated for 15 min in 30 % H2O2 
in methanol, before being immunostained with a peroxidase system using Vectastain® ABC kit 
(Vector Labs) according to the manufacturer’s protocol. Briefly, sections were blocked in normal horse 
serum from Vectastain Kit diluted in PBS with 0.1 % Tween for 20 min, followed by 1 h incubation 
with primary antibody (Pin1 monoclonal antibody Santa Cruz, 1:250 diluted in blocking buffer) to 
reduce not-specific background staining. Sections were then incubated with biotinylated universal 
secondary antibody for 30 min followed by Vectastain® Elite ABC reagent for another 30 min. Liquid 
Diaminobenzidine (DAB) (Thermo scientific) was used as a chromogenic agent for 5-15 min until the 
sample turns dark brown, and then sections were counterstained with Harris’s haematoxylin, 
dehydrated through an ascending graded alcohol series and mounted on cover glasses with mounting 
medium. Positive controls were included in each batch and negative controls were prepared by 
replacing the primary antibody with blocking solution. 
 
Gene expression analysis. Total RNA was extracted using Trizol reagent (Invitrogen) and subjected to 
DNase-I (Ambion) treatment. For microarray analysis three biological mRNA replicates for each group 
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(siPin1 or sip53) were hybridized on Affymetrix GeneChip Human Genome U133A 2.0 array. For 
quantitative RT-PCR mRNA was transcribed using Superscript III (Invitrogen). Real-time PCR was 
performed using SYBR Green PCR master mix (Applied Biosystems) and StepOne Plus cycler 
(Applied Biosystems). 
 
Real-time PCR primers: 
 
Name  Sequence (5’-3’) 
BUB1 f ATTCAAGCCACAGAGTGGAGCAG 
BUB1 r AGAACTTGTGTTGGCAACCTTATGTG 
C21ORF45 f GCGACTCGCTGAGCTGGGTG 
C21ORF45 r CCCCGCGCAGCACAAAGTCT 
CCNA1 f TGAGGCGACAAGGAGTGTG 
CCNA1 r AGAATGGATCTGCTTCAAGTAGAC 
CCNE2 f TGAGCCGAGCGGTAGCTGGT 
CCNE2 r GGGCTGGGGCTGCTGCTTAG 
CENPA f CTTCCTCCCATCAACACAGTCG 
CENPA r TGCTTCTGCTGCCTCTTGTAGG 
CPSF6 f AGGGGCTGTTCCTGGTGGGG 
CPSF6 r GGCCCAGCTAGAGGAGGAGGC 
DEPDC1 f TGGGTATTATCTGCCATGAAGTGCCT 
DEPDC1 r AGGTTGCAGCAAGCCCAAAATGT 
DUSP5 f CCTGCGCGACCCACCTACAC 
DUSP5 r TGGACCAGGACCTTGCCTCCC 
EPB41L4B f CGACGGGACCGAAGTGAGCG 
EPB41L4B r CAGTGCGCAACCTGGGCAGA 
FAM64A f CTCCAGGCTGCAGCTCGCTC 
FAM64A r CAGCCGGGTGCTCTTCTGGC 
Fbxw11 f AGAATGGCAGCGAGTGATCT 
Fbxw11 r GCCATCTGTGGGTCTGTTTT 
G3BP1 f CTTATGTCCATGGGGGATTG 
G3BP1 r TCACCTGGACTACCACACCA 
GDF15 f CGGCCCCTGCAGTCCGGATA 
GDF15 r GTCCCACGACCTTGACGCCG 
HHEX f GCGAGAGACAGGTCAAAACC 
HHEX r AGGGCGAACATTGAGAGCTA 
LAMB1 f TACTGCAAGCGTCTGGTGAC 
LAMB1 r AACCAGGTTCCACTTCGTTG 
LAMC2 f CCAGAGCCAAGAACGCTGGGG 
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LAMC2 r TCATGGGCCGCAGTTGGCTG   
NCAPH f GAGGAGCCTGCCCCCTGTCA 
NCAPH r TGGGCCTCCTGCTGCTGACT 
PARP3 f (-) TCCCCGGCCTCTGGCGATT 
PARP3 r (-) AGGGCTTCGGCTTTGGAGCCAT 
ST6GALNAC f TTACTCGCCACAAGATGCTG 
ST6GALNAC r GCACCATGCCATAAACATTG 
TIMP3 f CAGCTGGAGCCTGGGGGACT 
TIMP3 r TGCCGAAGGGCCCCTCCTTT 
WDR67 f AGGCAACAAGGAGAGCGGCA 
WDR67 r AGCAGTCGCCTGTGCCATCA 
 
Microarray data analysis. Raw gene expression intensities were normalized at the probe level using 
the RMA algorithm as previously described (Irizarry et al., 2003). The low-level analysis of microarray 
data was performed in the R/Bioconductor environment using, in particular, the limma and affy 
microarray packages (http://www.R-project.org). The public datasets used (GSE7390, GSE2990, 
GSE3494, GSE1456) were downloaded from Gene Expression Omnibus (GSE7390, GSE3494, 
GSE299) or from authors’ data web site (GSE1456, http://www.meb.ki.se/~yudpaw/). Gene annotation 
for all the platforms considered was obtained from R-Bioconductor metadata packages (Gentleman et 
al., 2004). Differential gene expression analysis of all datasets considered in the present study was 
investigated using functions and methods implemented in the R/Bioconductor (Gentleman et al., 2004; 
Smyth, 2004). Briefly, a fixed effects linear model was fitted for each individual feature to estimate 
expression differences between groups of samples to be compared. An empirical Bayes approach was 
applied to moderate standard errors of M-values (Smyth, 2004). Finally, for each analyzed feature 
moderated t-statistics, log-odds ratios of differential expression (B-statistics), raw and adjusted P 
values (FDR control by the Benjamini and Hochberg method) were obtained. 
 
Microarray survival data analysis. Cox proportional hazards model was fitted to test for the 
association between gene expression of common top down-regulated genes and survival time (Desmedt 
et al., 2007). In particular Cox proportional hazards model (Wald statistic) was fitted for each gene to 
test for an association between gene expression and survival to produce coefficient rankings associated 
with clinical data. From the clinical associated rank, we selected genes with score greater than 3, 
obtaining in this way the “ten gene signature”. To verify the correlation of the ten gene signature and 
breast cancer clinical data, a Mantel-Haenszel test was applied to the other normalized datasets we used 
(GSE2990, GSE3494, GSE1456) (survival R package). A univariate linear model was applied to the 
normalized datasets to calculate P value between samples among ten-genes-signature-expression 
positive and negative samples. The median values of the classifiers were used as threshold. 
Survival curves were constructed using Kaplan-Meier methodology (survival package). Log-rank tests 
assessed differences in ten genes signature expression and time to distant metastasis (if available) or 
overall survival time. 
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Chromatin immunoprecipitation. Cells were cross-linked in culture medium with 1 % formaldehyde 
for 10 min, neutralized using 125 mM glycine in PBS and washed in PBS. Nuclei were obtained by 
lysing scraped cells in hypotonic buffer (5 mM Pipes pH 6.8, 85 mM KCl, 0.5 % NP-40 and protease 
inhibitors) and centrifugation. The nuclei pellet was resuspended in RIPA 100 mM buffer (20 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Na-Deoxycholate, 0.1% SDS 
supplemented with protease inhibitors). Chromatin was sonicated to 500-800 bp average fragment size 
and pre-cleared for 1 h at 4°C with protein A/G PLUS-Agarose (Santa Cruz). Agarose was removed by 
centrifugation and an aliquot of supernatant was taken as input. Chromatin was immune-precipitated 
overnight at 4°C with p53 DO1 (Santa Cruz). As a negative control for immune-precipitation, IgGs 
purified from mouse serum were used (Santa Cruz). DNA protein complexes were recovered with 
protein A/G PLUS-Agarose and washed sequentially with RIPA 100 mM buffer, RIPA 250 mM buffer 
(20 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Na-Deoxycholate and 
0.1% SDS), LiCl solution (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40 and 
0.5% Na-Deoxycholate) and TE. RNase treatment was performed in TE for 30 min at 37°C and to 
reverse cross-linking samples were treated o.n. at 68°C adding an equal volume of proteinase K 
solution (200 mM NaCl, 1% SDS and 0.3 mg/ml proteinase K). In parallel, input was treated in the 
same way. After phenol/chloroform extraction and ethanol precipitation samples were resuspended in 
H2O. Co-immuneprecipitated DNA was analyzed by Real Time PCR on a StepOne Plus cycler 
(Applied Biosystems), using SYBR Green Universal PCR Master Mix (Applied Biosystems). Promoter 
occupancy was calculated as percent of chromatin input using the 2-ΔCt method. 
 
ChIP primers: 
 
Name  Sequence (5’-3’) 
BUB1 f GGGCTGCCTCACACCCGTTT 
BUB1 r ACACCTGCCCTTCCAGTGGG 
C21ORF45 f GGTGCTGAGCAGCTGGTGCAAA 
C21ORF45 r TGCGGGGTCACATTACTCCCCT 
CCNE2 f AAATCCAGGAGTTGCAGTGG 
CCNE2 r ACTCTCAGGGGCTCCTTCTC 
CENPA f ACTTCCCAAGGGTCACACAGTCA 
CENPA r TGTGGCAGAATGGGACAGGCG 
CPSF6 f TGGCAATGAATGCGAGAGGAAGGT 
CPSF6 r CCCCGGGCATTCTGTGAACGG 
DEPDC1 f AGGGCCAGGCAGAAAAACCGT 
DEPDC1 r CGGGTTTCCCTGGCGCTGTT 
EPB41L4B f AGTGCAGCAGTGAGACGGGGA 
EPB41L4B r ACCCCAGAGGCTAGTCCGAAGG 
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FAM64A f ATCGGGGCGTCTGGTGGGAA 
FAM64A r CGAGGAGGGGAGGCAGGGTC 
NCAPH f CCCTGCCTGCATCTGTGCCA 
NCAPH r GCAGGCAAAGAGGTTGCCTTTGT 
WDR67 f CACGAGGCTCCCAAAGGGCG 
WDR67 r AAAATCCGCCCAAGCGGCCA 
(-) DEPDC1 f GGCTTGGGACGCCTCACGAT 
(-) DEPDC1 r GCCCATGAACTGCCTAGCTGTGG 
 
Wound healing-based assay. To achieve quantification of cell migration in 96-well plates the Oris 
Cell Migration Assay was used according to the manufacturer’s instructions (Platypus Technologies). 
This assay is a modified wound healing assay that uses proprietary silicone inserts to restrict cell 
seeding from an area in the centre of the wells; removal of these inserts creates an area devoid of cells 
– the migration zone (2 mm diameter) – into which the neighbouring seeded cells may migrate. Pools 
of 4 different siRNAs per gene target (Qiagen, 50 nM final concentration) were transfected with 
Lipofectamine RNAiMax (Invitrogen, 0.3 µl/well) using a reverse transfection protocol. Transfections 
and cell seeding (2 x 104 cells/well) were performed robotically on a Hamilton STARlet liquid 
handling robot (Hamilton Robotics). 48 h after siRNA transfection, the silicone inserts were removed 
creating the migration zone in the centre of each well. Cells were then stained with Hoechst 33342 (0.2 
µg/ml) for 10 min, following which the medium was replaced by complete medium and cells were 
imaged to establish the starting point for the migration. To assess the effect of the different siRNAs on 
cell migration, cells were imaged again 24 h after removal of the inserts, i.e. 72 h after siRNA 
transfection. Image acquisition was performed using an ImageXpress Micro automated high-content 
screening microscope (Molecular Devices) equipped with a 4x objective; a total of 4 fields were 
acquired per well in order to cover the migration zone completely. Automated analysis of cell 
migration was performed in MetaXpress software (Molecular Devices) using a custom developed 
journal, which stitched the different fields of each well to produce a single image, and then computed 
the area devoid of cells. Percentage of cell migration was calculated by comparing the area without 
cells calculated for each well immediately after removal of the inserts to that after 24 h of cell 
migration. The effect of the different siRNAs on proliferation and cell viability was assessed, in 
parallel experiments, by measuring cellular ATP 48 h after silencing, i.e. the time point corresponding 
to the beginning of the migration experiments, using the ATPlite-1step ATP detection system 
(PerkinElmer) according to the manufacturer’s instructions. 
 
GeneID Gene Symbol siRNA catalog# (a) 
Average migration  
(b) 
Average viability  
(c) 
699 BUB1 
SI00288155 
SI00288148 
SI04434430 
SI04434423 
37.75 ± 6.69 115.80 ± 12.97 
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GeneID Gene Symbol siRNA catalog# (a) 
Average migration  
(b) 
Average viability  
(c) 
54069 C21orf45 
SI03246866 
SI03246530 
SI04296467 
SI03163804 
58.55 ± 0.96 105.70 ± 10.91 
9134 CCNE2 
SI02653238 
SI02653035 
SI00067263 
SI00067256 
38.87 ± 9.19 97.73 ± 6.79 
1058 CENPA 
SI04230177 
SI04151749 
SI04146709 
SI04138491 
72.16 ± 4.40 114.55 ± 26.28 
11052 CPSF6 
SI04339692 
SI04336563 
SI03139563 
SI00353213 
38.03 ± 4.21 96.34 ± 11.42 
55635 DEPDC1 
SI04342366 
SI04211228 
SI03241616 
SI03176530 
17.53 ± 4.14 82.38 ± 2.95 
54566 EPB41L4B 
SI04321723 
SI04151546 
SI03166380 
SI00380324 
50.27 ± 4.37 105.64 ± 21.07 
54478 FAM64A 
SI02777887 
SI03074771 
SI03063123 
SI00123774 
58.17 ± 3.57 107.68 ± 2.20 
 LacZ see above 69.05 ± 1.93 100.00 ± 16.55 
23397 NCAPH 
SI04224766 
SI04155683 
SI04150027 
SI00313600 
54.98 ± 4.04 82.07 ± 3.75 
5300 PIN1 
SI02662667 
SI02662128 
SI03092047 
SI03068086 
28.51 ± 6.75 84.89 ± 4.63 
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GeneID Gene Symbol siRNA catalog# (a) 
Average migration  
(b) 
Average viability  
(c) 
7157 TP53 
SI02655170 
SI04384079 
SI02623754 
SI02623747 
48.02 ± 8.06 98.96 ± 19.32 
93594 WDR67 
SI04365326 
SI04338411 
SI04143132 
SI05166987 
58.15 ± 5.74 112.04 ± 9.06 
(a) siRNA catalog # – catalogue numbers for individual siRNAs sequences (all siRNAs from Qiagen) 
(b) average migration – percentage of initial area occupied by cells after 24 h migration (average ± s.d.) 
(c) average viability – percentage of cell viability at beginning of migration experiment, i.e. 48 h after siRNA treatment (average 
± s.d., normalized for LacZ) 
 
Tissue microarray construction. The tissue microarray (TMA) used in this study consisted only of 
historical breast cancer samples, donated from each of 212 primary previously untreated and otherwise 
unselected tumours. The TMA was constructed using a manual tissue arrayer (Beecher Instruments 
Inc) with an average of six cores, each 0.6mm in diameter. A specialist consultant breast pathologist 
marked representative tumour areas from each case on haematoxylin and eosin stained slides prior to 
core removal. The results generated were exported via Aperio Web Services. Overall survival was 
calculated from date of treatment start to date of death, or date of censor if alive. Survival curves were 
constructed using Kaplan-Meier methodology. Log-rank tests assessed differences in tumour 
characteristics. Adjuvant chemotherapy typically consisted on anthracycline-based regimens. 
 
Digital virtual microscopy and scoring. Stained TMA slides were scanned (Scancope XT, Aperio 
Technologies), at a x40 objective and archived within the ‘Aperio Spectrum Plus + TMA’ database 
(version 9.0.748.1521). Breast cancer TMA scoring was conducted in isolation blinded to other data. 
The scoring was re-checked by the same pathologist via standard optical microscopy using a Nikon 
Eclipse E600 microscope. Only cores containing tumour were assessed; unsuitable cores included those 
comprising less than 20% of the expected core size, missing cores, overlapping cores, cores of fat, 
stroma or normal breast epithelium. Only invasive malignancy was scored; in situ malignancy and 
background epithelium and stroma were ignored. Antibody staining was assessed on each suitable core 
and scored using the “Quick Score” method (Detre et al., 1995). Briefly, the proportion of positive cells 
was estimated and given a score on a scale of 1 to 6: 0 - 4% = 1, 5 - 19% = 2, 20 - 39% = 3, 40 - 59% = 
4, 60 – 79% = 5, and 80 - 100% = 6. The average intensity of the positively staining cells was 
estimated and given a score of 0 to 3: no staining = 0, weak staining = 1, intermediate staining = 2, and 
strong staining = 3. The Quick Score was then calculated by multiplying the percentage of cells 
staining score by the intensity score to give a maximum value of 18. As most cases had more than one 
core of tumour suitable for scoring, an overall, single Quick Score for each tumour, and therefore each 
patient, was generated. In addition, the cellular localization of the antibody staining was noted to be 
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cytoplasmic, and nuclear, consequently each compartment was scored separately, yielding two Quick 
Scores per patient. 
 
Multivariate analysis using a Cox proportional-hazards model. The analysis of the death risk for 
the 212 tumours from the TMA was conducted using Cox proportional-hazards regression modelling. 
We examined the relationship between overall survival and the presence of TP53 missense mutation 
and Pin1 levels and other predictors commonly used in the clinical practice, including tumour size and 
grade, node infiltration, oestrogen receptor status (ER status), progesterone receptor status (PGR status) 
and HER2 status. We fitted Cox proportional-hazards regression model first by using clinical variables 
only and then adding TP53 missense mutation and Pin1 level variables. Clinical parameters were 
treated as follow: 
- Tumour size: continuous variable; 
- Tumour grade: grade 1, grade 2, grade 3; 
- Node infiltration: negative if less or equal to 4 (0), positive > 4 (1) 
- ER status: negative if less or equal to 4 (1), positive > 4 (0) 
- PGR status: negative if less or equal to 4 (1), positive > 4 (0) 
- HER2 status: positive staining or negative staining (0, 1) 
- Pin1 status: positive nuclear staining of Pin1 > 5 (1), negative if less or equal to 5 (0). 
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